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I

Abstract
Osteoarthritis (OA) is one of the most prevalent musculoskeletal diseases in the world. Our
laboratory has shown that epidermal growth factor receptor (EGFR) signalling is involved
in the process of cartilage degeneration in OA. Regulation of EGFR signalling by mitogeninducible gene 6 (Mig-6) and dual specificity phosphatase 1 (DUSP-1) allows for signal
modulation, and mouse models have linked these proteins to joint pathologies. Failure to
control EGFR signalling may be involved in OA progression leading to my overarching
hypothesis: regulation of EGFR signalling is essential for maintenance of joint health.
I initially tested the role of Mig-6 in cartilage health using cartilage-specific deletion of
Mig-6 in a mouse model. Using various histological and imaging techniques, we
demonstrated that these animals show increased anabolic activity in articular cartilage, as
well as the formation of chondro-osseous nodules in their knee joints within the first 3
months. These mice did not develop severe OA as I predicted, however, there were early
signs of developing articular cartilage pathology.
To assess the role of Mig-6 in elderly cartilage, we employed the same mouse model but
aged these animals to 21 months, near the end of their life span. These KO animals
exhibited similar knee phenotypes, however, no abnormal growths were observed in the
ankle and elbow joints which showed enhanced cartilage thickness. Only minor signs of
OA were noted. Using an inducible system to delete Mig-6 from cartilage of 3 week old
mice, we found limited evidence of increased anabolic activity at 12 weeks. These studies
demonstrate that Mig-6 may be playing an important role during development and that loss
of Mig-6 may positively impact cartilage health.
Finally, I examined the knee joints of whole body Dusp1 null mice at 21 months of age for
signs of OA. Both Dusp1 null and control mice showed similar signs of OA, indicating that
DUSP-1 mediated regulation of signalling downstream of EGFR is not essential to prevent
spontaneous OA progression.

II

Taken together, these data demonstrate that EGFR signalling regulated by both Mig-6 and
DUSP-1 is important in joint homeostasis, and has revealed a potential target in Mig-6 for
future cartilage regenerative treatments.

Keywords
Epidermal growth factor receptor, transforming growth factor alpha, mitogen-inducible
gene 6, dual specificity phosphatase 1, p38, ERK, osteoarthritis, articular cartilage, ectopic
cartilage, synovial joint, skeleton, Sox9
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Chapter 1

1

Literature Review

1.1

The Development of the Skeleton

The development of the skeleton marked an important step towards the evolution of
mammals. A rigid framework allows for attachment of muscle groups and protection,
providing an evolutionary advantage for these early vertebrate creatures [1]. Without a
skeletal system, terrestrial life as we know it today would be impossible, as large creatures
would collapse under their own weight [1,2]. The skeleton is also highly important in
regulation of blood calcium and phosphate, and may also be an important endocrine organ
system [3–6]. Modern mammalian skeletons are primarily made up of two different tissues
types: bone that forms the framework of the skeleton, and cartilage that enables the bones
to interface and form joints and articulate through many degrees of motion. Both of these
tissue types share a common progenitor cell of mesenchymal origin [7]. The 206 bones that
make up the human skeleton can be roughly classified into 3 categories based on their
location: craniofacial (skull), appendicular (limbs), and axial skeleton (vertebra and ribs).
The bones that comprise the appendicular and axial skeleton largely form through a process
called endochondral ossification, which requires a cartilage template prior to replacement
by bone [8]. The craniofacial bones, particularly the flat bones of the skull, form through a
process that does not require a cartilage template and is called intramembranous
ossification [9]. However, with few exceptions, both processes require the prior
recruitment of mesenchymal precursor cells to the location of the future skeletal element.
These precursor cells form condensations in a general template of the future bone [10].
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1.1.1

Intramembranous Ossification

Only a small number of bones form through intramembranous ossification (IO), including
the scapula, pelvis, clavicles, and the flat bones of the skull [9]. In IO, mesenchymal
progenitor cells differentiate directly into osteoblasts that produce osteoid the extracellular
matrix (ECM) that will then support crystallization of the mineral content that gives bone
its rigidity [9,11]. This process is largely driven by the two transcription factors runt-related
transcription factor 2 (RUNX2) and downstream osterix [12]. In fact, the mesenchymal
precursor cells (also called osteochondral progenitors) of genetically modified mice
deficient in either of these factors fail to differentiate into osteoblasts and produce bone,
leading to embryonic death of these mice [12].

1.1.2

Endochondral Ossification

The long bones that largely make up the appendicular skeleton (ex. tibia, femur, radius,
ulna) form through a process called endochondral ossification (EO) [8,13,14]. While the
end result is similar to IO with osteochondral progenitor cells eventually forming mature
bone, the long bones must first go through a phase in which a cartilage template is
incrementally replaced by bone [8,14]. This cartilage template is formed by cells called
chondrocytes that share a common osteochondral progenitor cell origin with osteoblasts
[7,14]. Both cell lineages begin with progenitor cells producing the transcription factor
SRY (sex determining region Y)-box 9 [SOX9] with concomitant Runx2 expression [7,14].
Cell fate is determined when the osteochondral progenitor commits to either Runx2
expression driving the cell to the osteoblast lineage, or Sox9 which drives chondrogenesis
[7]. SOX9 is considered the ‘master regulator’ for the chondrocyte phenotype, and in this
role it directly regulates genes that are necessary for chondrocyte function and cartilage
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production [15]. Expression of ECM protein genes Col2a1 and Agc1 that encode for
collagen II and aggrecan, respectively, are regulated by SOX9, and are essential for
cartilage structure and function [15]. In fact, SOX9 in concert with SOX5/6 (the “Sox
Trio”) is essential for the formation and maintenance of permanent cartilage in the skeleton
[16].
Following the formation of the mesenchymal condensation, EO proceeds with the
differentiation of osteochondral progenitors within the condensation to a chondrocyte
lineage, with peripheral cells lining the template forming a perichondrial lining [17].
Perichondrial cells play a role in isolating the growing skeletal element from surrounding
mesenchyme environment, and retain the ability to differentiate into chondrocytes or
osteoblasts [13,17]. Cells within the mesenchymal condensation proliferate and begin to
produce collagen II and aggrecan under the control of the Sox Trio [8,13,16]. As the
cartilaginous bone template grows through chondrocyte proliferation and matrix
production, a zonal structure begins to form along the long axis of bone formation [8]. Cells
near the center of the template stop proliferating and grow from a characteristic compact
rounded chondrocyte phenotype to an expanded hypertrophic cell phenotype, forming the
‘hypertrophic zone’ [18]. Neighboring cells continue to proliferate and begin to form
columns of clonal cells along the axis of bone growth, these columns form the ‘proliferative
zone’ [8]. Chondrocytes near the ends of the bone template do not show active cellular
proliferation and are more quiescent forming the ‘resting zone’ [8,13]. Collectively these
zones form what is called the cartilage growth plate (Fig. 1.1).
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Figure 1.1 The Growth Plate The growth plate is involved in development and
endochondral ossification, and is organized into distinct zones of chondrocytes. The resting
zone near the end of the bone is composed of relatively quiescent chondrocytes with a
rounded phenotype. Chondrocytes enter the proliferating zone and form coin-like columns
of rapidly proliferating clonal cells. As these cells exit the cell cycle they being to enlarge
and enter the prehypertrophic zone. Terminally differentiated chondrocytes enter the
hypertrophic zone and exhibit a large cell volume relative to the resting chondrocytes.
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Figure 1.1 The Growth Plate
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1.1.3

The Growth Plate

Largely deprived of oxygen and nutrients, chondrocytes in the hypertrophic zone of the
growth plate stop proliferating and change programming to produce a unique set of ECM
proteins, degradative enzymes, and signalling molecules [13,14]. The production of
collagen X rather than collagen II and aggrecan is a hallmark of the hypertrophic
chondrocyte phenotype, and is commonly used as a cell marker [14,19,20]. Hypertrophic
chondrocytes release vascular endothelial growth factor (VEGF) which recruits vascular
invasion into the center of the growth plate [13,14]. Along with nutrients and oxygen, this
vasculature brings in osteoclasts that are involved in cartilage template removal so that
osteoblasts can lay down new bone matrix [8,14]. This region of new bone formation is
called the primary ossification center, which will ultimately expand to form the diaphysis
of the mature bone [13,14,17]. Hypertrophic chondrocytes also produce degradative
enzymes including matrix metalloproteinase 13 (MMP-13) and aggrecanases that further
assist in matrix removal through cleavage of the collagen II and aggrecan network
respectively [8,14,21,22]. Ultimately, hypertrophic growth plate chondrocytes will
undergo apoptosis, or as recent work suggests, may transdifferentiate to contribute to the
osteoblast pool that will replace the removed cartilage matrix with bone [19,20,23,24].
Cells lining the hypertrophic zone differentiate to osteoblasts and contribute to the
formation of the cortical bone collar and periosteum. Cells between the hypertrophic zone
and the neighboring proliferating zone are called pre-hypertrophic chondrocytes and
exhibit an intermediate phenotype between the two zones [13,14].
The proliferative zone is composed of clonal columns of coin shaped proliferating
chondrocytes and develops parallel to the direction of bone growth, in a process driven and
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regulated by various local and systemic factors [13,15,16]. Along with the expansion
caused by the increased cellular volume of hypertrophic cells, this proliferative activity
drives the elongation of the bone [13]. Vitamin D, growth hormones and thyroid hormones
are all systemic factors that regulate the proliferating zone chondrocytes [25]. However,
local growth factors including fibroblast growth factors (FGFs) and bone morphogenetic
proteins (BMPs) also play a role [13,26]. The parathyroid hormone related peptide (PTHrP)
and Indian hedgehog (IHH) signalling axis permits fine tuning of cellular activity in the
proliferative zone and initiation of hypertrophy in the pre-hypertrophic zone [13,14,17,27].
PTHrP produced by both chondrocytes and perichondrial cells at the end of the bone
(resting zone) diffuses through the proliferating zone and maintains these cells in a
replicative status [13,17]. The PTHrP concentration diminishes farther from the end of the
bone and as these chondrocytes exit the cell cycle and enter the pre-hypertrophic zone, they
release IHH that has a number of effects on local chondrocytes and the perichondrium [13].
IHH signals back to the end of the bone and maintains PTHrP release, and also induces
perichondrial cells to become osteoblasts and form the bone collar [8,13]. This feedback
loop helps to maintain zonal organization in the growth plate [13,14].

1.1.4

Secondary Ossification Center

As the bone develops and increases in size, a secondary ossification center forms on either
end of the bone and will become the bone epiphysis [14,17]. Similar to the primary
ossification center, the secondary ossification center forms when chondrocytes undergo
hypertrophy and recruit blood vessels that carry osteoblasts and osteoclasts to lay down
new bone [14,17]. The growth plate (now also called the metaphysis) consists of the same
zonal arrangement of chondrocytes (Fig. 1.1), sandwiched between the primary
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ossification center, and the new secondary ossification center at the end of the bone
[13,14,17]. However, a region at the very end of the bone retains chondrocytes that will
eventually form the articular cartilage that enables bones to smoothly interface, and
articulate with one another in the future joint [14,17]. Closure of the growth plate consists
of the slowing and eventual termination of chondrocyte proliferation, with replacement by
bone that occurs in humans once skeletal maturity is reached during late puberty [28].
Interestingly, mouse growth plates do not close at sexual maturity, however it seems that
high estradiol levels as experienced by humans during late puberty can cause the growth
plate to close in mice when delivered exogenously [29].

1.1.5

The ‘Bone’ in Bones

Bones consist of an organ unit made up of various tissues including cartilage, bone tissue,
blood vessels, and a marrow cavity filled with hematopoietic stem cells [14,17]. Bone
tissue is porous, and contains numerous channels for blood vessels, nerves and the
conduction of fluid flow important for transportation of small molecules, nutrients, and
information about mechanical loading [30]. The tissue itself consists of a mineralized
matrix comprising organic ECM proteins such as collagen I and additional non-collagenous
bone matrix proteins [31]. Matricellular proteins regulate the formation of hydroxyapatite
crystals that give the bone its rigidity, and may act as signalling molecules during bone
remodeling [4,31,32]. There are two general types of bone tissue serving functionally
similar but structurally unique purposes. Cortical bone composes the outer regions of all
skeletal elements and is densely arranged to provide structural stability and strength to the
skeleton [33]. Trabecular bone (also referred to as cancellous or spongy bone) is found near
the end of the long bones and in the inner regions of many other bones [33]. This type of
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bone is organized in a honeycomb-like network of bone spicules and further supports the
cortical bone, while accommodating free space for the marrow cavity [33]. Both types of
bone regularly undergo remodeling processes to repair both major and micro fractures, as
well as regulating blood mineral homeostasis [4,31,33,34].

1.1.6

Bone Remodeling

Bone is constantly being broken down and reformed to regulate blood calcium/phosphate
homeostasis, repair macro and micro bone fractures, and adapt to environmental challenges
[4,30]. Destruction of bone is mediated by hematopoietic stem cell lineage-derived
osteoclasts [34]. Osteoclasts form when receptor activator of nuclear factor kappa B ligand
(RANKL) and macrophage colony stimulating factor (M-CSF) stimulate precursor cells to
fuse and differentiate into multinucleated mature cells [34,35]. Activated osteoclasts bind
to the surface of the bone through interactions of their surface integrins with the bone
matrix to form a unique physiological structure called the ruffled border [34,35]. The
ruffled border vastly increases the surface area in contact with the resorption pit that forms
underneath the osteoclast [34,35]. The osteoclast then releases a high concentration of
hydrogen ions into the resorption pit, acidifying the local environment and freeing the
inorganic mineral content in the bone [34,35]. Additionally, proteinases including
cathepsin K and various MMPs such as MMP-9, as well as tartrate resistant acid
phosphatase (TRAP) are released that then break down the collagens and other ECM
proteins that make up the organic component of the bone [34–36].
Conversely, osteoblasts are responsible for laying down new bone during development and
in response to osteoclast-mediated bone resorption [34,36]. These cells are derived from
the same mesenchymal progenitor cells as chondrocytes, with RUNX2 driving their
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differentiation to mature osteoblasts [7,9,36]. Osteoblasts lay down a collection of ECM
proteins consisting primarily of collagen I, but also including other non-collagenous
structural proteins and signalling proteins [31,33]. This unmineralized matrix is called
osteoid, which through a poorly understood mechanism mineralizes when hydroxyapatite
crystals form in association with the bone ECM to form a rigid network [31,33].
Osteoblasts regulate the activity of osteoclasts through the release of RANKL and the
soluble receptor activator of nuclear factor kappa B (RANK)-like decoy receptor
osteoprotegerin (OPG) [33,34]. Together, osteoclasts and osteoblasts form the basic
multicellular unit (BMU) that over the course of weeks progressively breaks down and reforms bone in response to the needs of the organism [34].

1.2

Synovial Joints

Individual skeletal elements are generally connected by joints. There are three varieties of
joints that form between at least two apposing bones: cartilaginous joints connect the bones
through an interface of cartilage (ex. the intervertebral disc in the spine), fibrous joints are
connected via tough fibrous collagen rich tissue (ex. sutures between skull bones), and
synovial joints that contain a fluid filled space between the bones (ex. knee, ankle, elbow)
[33,37–39]. Synovial joints form through a process involving regulated cell death in the
joint interzone that will define the joint location, and is partially mediated by muscle
movement during embryonic development of the bone [37,40]. Growth/differentiation
factor 5 (GDF5), a member of the BMP superfamily, appears to be particularly important
both in the formation of joints and skeletal development in general as mice deficient in
GDF5 fail to correctly develop joints in the appropriate location and show stunted limb
development [37,41].
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Synovial joints function as a unit of many different tissue types acting together. At least
two bones apposing one another are supported by and anchor muscles that not only allow
for locomotion, but also ensure that joint stability and alignment are maintained [42].
Ligaments and other supportive fibrocartilaginous structures (ex. the menisci in the knee
joint) further protect joint alignment, distribute load, and prevent damaging overextension
or slipping of the joint [43]. The joint capsule and synovium surround the joint and prevent
the synovial fluid contained in the joint space from escaping [43,44]. Perhaps most
importantly, a layer of articular cartilage caps the bone and provides near frictionless
articulating surfaces for the joints to interface [43,45]. Subchondral bone immediately
beneath the articular cartilage supports the overlying tissue both mechanically, and through
exchange of nutrients and waste products [43,46,47]. An example of a synovial joint is the
knee, and is shown in Fig. 1.2 (left half).

1.2.1

Cartilage

Cartilage in general is a connective tissue that depending on the function required may
have very different mechanical and structural attributes. Subtypes of cartilage have been
defined largely based on their matrix content and function, and include: elastic, hyaline,
and fibro-cartilage [48–50]. Fibrocartilage is found in many supporting joint structures,
including the meniscus of the knee and the annulus fibrosis in the intervertebral disc of the
spine, and its ECM is made up largely of large collagen I fibers [50]. Elastic cartilage is
similarly composed largely of collagens but also contains a high proportion of elastin and
can be found in the ear and epiglottis [50]. Hyaline cartilage forms both articular cartilage,
and growth plate cartilage and is composed largely of collagen II [49,50].
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Figure 1.2 Diagram of a healthy and osteoarthritic joint (knee). This schematic
representation shows the effects of osteoarthritis (OA) encompassing the whole joint.
Healthy articular cartilage (blue) degenerates and may shed fragments into the synovial
fluid (yellow). The synovium (red) secretes lubricating molecules, however in OA it
becomes inflamed (synovitis) and releases inflammatory compounds into the joint.
Subchondral bone remodeling (stippling), and osteophytes may also develop in OA.
Supportive ligaments (central) help keep the joint in alignment, and disruption of these
structures may lead to OA. Not shown are the additional supportive ligaments (collateral
ligaments, etc.) and menisci that further support the joint and distribute load.
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Figure 1.2 Diagram of a healthy and osteoarthritic joint (knee).
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1.2.2

Articular Cartilage

The primary function of articular cartilage is to prevent excessive friction and wear,
allowing smooth articulation between interfacing surfaces in the joint [43,45]. To perform
these duties, cartilage has adapted an interesting structure and composition. Unlike many
other tissues in the body, healthy cartilage is completely aneural and avascular, and thus
depends largely on diffusion of water into and out of the tissue to transport nutrients and
waste [50,51]. Chondrocytes are the only resident cell type, and make up approximately
2% of the volume of human cartilage [51,52]. The bulk of the tissue is composed of a
complex network of ECM proteins collagen II, various proteoglycans including aggrecan,
and matrix crosslinking proteins [49–51]. Aggrecan is rich in charged glycosaminoglycan
(GAG) side chains that highly attract water. This is important for cartilage as water is
forced out of the tissue during loading, and the charged GAG molecules attract water back
into the tissue when load is released [51,53]. This combined with the structural strength
contributed by the collagen network makes cartilage a highly durable tissue [49]. However,
the relatively acellular, and completely avascular nature of cartilage severely limits its
ability for to repair [43,54]. Furthermore, due to relatively slow turnover of the matrix,
collagen in the cartilage may have a half-life of decades, and aggrecan may persist for
years, meaning the cartilage present at skeletal maturity is essentially the same throughout
life [43,55]. Buildup of advanced glycation end products (AGEs) on matrix proteins
through low turnover can alter the function of the ECM, and activate the pro-inflammatory
AGE receptor (RAGE) that may be involved in some forms of joint pathology [55].
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1.2.3

Cartilage Zonation

Cartilage is an anisotropic tissue, with variations in the organization of the matrix and
chondrocyte density tailored to suit the functions required at certain depths [49,51]. See
Fig. 1.3 for a descriptive diagram. In fact, the anisotropic organization of collagen in
cartilage and bone can be shown by picrosirius red staining using histology, which
enhances the birefringent effect of collagen and causes selective illumination of
specifically aligned collagen fibers under polarized light microscopy [56,57]. The surface
of articular cartilage is known as the superficial zone and is directly exposed to the synovial
fluid that bathes the joint space [51]. Chondrocytes present in this zone are flattened
relative to chondrocytes in deeper zones and express lubricin, a unique lubricating protein
encoded by the Prg4 gene, that decreases the coefficient of friction of the joint surface
[51,58]. The collagen matrix in this region is organized parallel to the surface of the joint,
with the lowest concentration of aggrecan relative to deeper zones [51]. The superficial
zone possess the greatest tensile strength in the cartilage, which enables it to cope with the
shearing and compressive forces experienced during articulation and loading [51]. Below
the superficial zone, mid-zone cartilage has a lower cellular density, however the
chondrocyte phenotype more closely resembles the typical rounded resting chondrocyte
[51,59]. The matrix of the mid-zone has much higher aggrecan content, with collagen
fibers in this zone showing less spatial organization relative to the superficial cartilage [51].
Deep zone cartilage and calcified cartilage show the lowest concentration of chondrocytes
and collagen content [51]. The deep zone and calcified cartilage are separated by a
meandering line of mineralization visible in histology and referred to as the ‘tidemark’
[51]. The proposed purpose of this calcified cartilage layer is to provide an intermediate
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Figure 1.3 Articular cartilage organization. Articular cartilage is organized into zones
with different cellular, structural, and mechanical properties. The superficial zone (SZ) is
in direct contact with the synovial fluid, and consists of collagen fibrils and elongated
chondrocytes running parallel to the articular cartilage surface. The mid-zone (MZ) is
populated by chondrocytes in a more typical spherical phenotype at a lower density relative
to the SZ. Collagen fibrils in the MZ are more randomly organized that the SZ. The deepzone (DZ) consists of chondrocytes in a roughly columnar organization, with collagen
organized roughly perpendicular to the surface and entering the underlying calcified
cartilage (CZ). The tidemark (TM) forms a visible demarkation point between the calcified
cartilage (CZ) and and overlying non-calcified cartilage. Chondrocytes in the CZ are
enlarged, and exhibit a hypertrophic-like phenotype. Proteoglycan content (largely
aggrecan) increases from the SZ to the DZ and is indicated by the red shading.
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Figure 1.3 Articular cartilage organization
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region of tissue stiffness between the soft overlying non-calcified cartilage, and the
relatively stiff structure of the underlying subchondral bone, thus preventing the cartilage
from shearing away [51,60]. Increasing aggrecan concentration in deeper zones of cartilage
ensures that water is electrostatically drawn back into the tissue following loading,
allowing the tissue to rebound and maintain elastic strength [51].

1.2.4

Cell Signalling in Chondrocytes

Despite the relative isolation of chondrocytes from others cells in the body, signalling
readily takes place within the cartilage. Chondrocytes can self-stimulate via autocrine
signalling mechanisms, as is seen with epidermal growth factor receptor (EGFR) and
release of cell-produced epidermal growth factor (EGF) [61]. Membrane bound factors can
also bind their respective receptors on the cell surface through juxtacrine signalling, as has
been shown with unprocessed transmembrane transforming growth factor alpha (TGFα)
that can also bind EGFR [61,62]. Further juxtacrine signalling pathways include the cellmatrix interactions mediated by integrins, varieties of which can bind a vast array of
cartilage ECM proteins including collagen II and fibronectin as well as certain cleaved
matrix proteins, and may additionally contribute to chondrocyte mechanosensing of
external forces [30,63,64]. Endocrine signalling takes place in articular cartilage, with
chondrocytes responding to systemic vitamin D, thyroid hormone, sex hormones and
adipokines, among various other hormones [25,65]. In fact, localized inflammation caused
by systemic inflammatory factors or those released within the joint may be a driving force
for the various diseases that can detrimentally affect cartilage and other joint tissues
[59,66].
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1.3

Arthritis

Diseases of the joint are as old as the foundation of joints themselves, as shown by evidence
of forms of arthritis in the fossil records of ancient reptiles and dinosaurs [67,68].
Dysfunction and disease of joints can take many forms, with many associated etiologies
and pathologies [69,70]. Arthritis is a disease of the synovial joint characterized by the
breakdown of articular cartilage, leading to pain and dysfunction for the afflicted individual
[46]. The most prevalent forms of arthritis are rheumatoid arthritis (RA), which is driven
by systemic and local inflammatory breakdown of bone and cartilage in the joint, and
osteoarthritis (OA), which has been considered a more ‘wear and tear’ disease in the past
but is now thought to have a more complex etiology [43,69–71]. This thesis is focused on
osteoarthritis.

1.3.1

Socioeconomic Burden of Osteoarthritis

Osteoarthritis is one of the leading cause of disability in the world, with more than 10% of
adults exhibiting symptoms of the disease [72,73]. The most well defined risk factor for
the disease is aging, with over 60% of men and 70% of women over the age of 70 showing
radiographic evidence of knee arthritis [74]. Indeed, this is most likely an underestimate as
early and mid-stage OA are very difficult to diagnose, and typical radiographic evidence is
not apparent until the end stage of the disease [43,46]. Symptoms of pain and stiffness
typically bring attention to the disease, however by this stage serious degenerative
processes have set in and treatment methods are currently lacking [72,73]. The symptoms
of pain and stiffness bring with them serious issues of disability that limit physical activity
and impact the quality of life of affected individuals [69,72]. Disability in the form of
movement limitation is present in over 80% of persons with OA, and over 10% will require
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outside assistance to perform daily tasks [72]. As the disease is currently incurable and
progresses for perhaps decades, the direct costs of treating the disease are immense,
accounting for 1 – 2.5% of the gross domestic product for 1st world countries [43,72]. The
indirect costs may be nearly 8-fold higher, and consist largely of lost work time due to
absenteeism, decreased productivity, early retirement, and premature death [72].
Furthermore, loss of work hours for caregivers attending to disabled individuals may also
contribute to economic impact [72].

1.3.2

Risk Factors

Osteoarthritis can be broadly (perhaps crudely) categorized as either: primary (idiopathic)
or secondary (post-traumatic) [43,75,76]. The causes of primary OA are not fully
understood, however some risk factors for the disease have been established as: increasing
age, obesity, sex (female), and genetics. It is uncommon to see primary OA in those under
the age of 40, however varieties of the disease do seem to affect younger individuals
[43,69]. The influence of genetic factors has also been well established in twin studies,
with the heritability of OA in the spine, hip, and hand estimated at over 60% [77,78]. In
comparison, heritability of knee OA has been estimated to be lower than 50%, perhaps due
to the prevalence of secondary OA in this joint over others [77]. However, retrospective
genome-wide association studies (GWAS) and candidate gene studies have uncovered very
few associated genes, with those identified playing roles as structural ECM proteins
(Col6a4), inflammation-related (Ptgs2), or developmental genes in bone/joint formation
(Gdf5, Dio2) [78,79]. Secondary osteoarthritis, on the other hand, has a better understood
etiology initiated typically by trauma to the affected joint [43]. Direct impact to the articular
cartilage or subchondral bone can cause direct death and dysfunction of chondrocytes, or
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cause subchondral bone changes that initiate overlying cartilage damage [75,80]. Damage
or laxity within the supporting ligaments (as seen in catastrophic anterior cruciate ligament
[ACL] rupture) can disrupt normal joint alignment, leading to increased abnormal loading
and subsequent articular cartilage damage [43,75]. It is currently debated as to whether
surgical repair of an ACL rupture is medically warranted, as outcomes have generally been
poor, however, animal models demonstrate that there may be benefits for a subset of
patients [81]. Obesity also seems to be a risk factor for both forms of the disease, with
increased weight leading to higher impact forces experienced by articular cartilage,
particularly the large weight bearing joints of the knee and hip [43]. However, obesity is
also associated with OA in non-weight bearing joints such as the hands, indicating that
additional factors like adipokines or systemic inflammation associated with obesity may
be involved [43,82,83]. While there may indeed be additional different subtypes of OA
with varying etiology and pathobiology, it seems that the disease progresses to a similar
end stage characterized by articular cartilage loss, and pathological bone remodeling [43].

1.3.3

Osteoarthritis Pathobiology

Previous thoughts that OA is exclusively a disease of the articular cartilage are likely not
correct. It now appears that OA is a disease involving the entire joint, however the tissue
that initiates the disease remains debated [43,80,84]. Indeed, the subchondral bone,
meniscus, supportive ligaments, synovium, in addition to the articular cartilage, are all
affected by the disease process, and contribute to pathology [43]. Please see Fig. 1.2 for a
diagram of healthy joint tissue in comparison to an OA afflicted joint.
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1.3.4

Articular Cartilage in Osteoarthritis

While tissues of the entire synovial joint do play a role in the disease, the hallmark of OA
remains degeneration of the articular cartilage [43,80]. Changes to the structure and
composition of the articular cartilage ECM begin early in the disease with the loss of GAGcontaining matrix proteins like aggrecan near the surface of the cartilage [43,51,85].
Following loss of GAG content, the collagen network itself begins to break down, resulting
in fibrillation of the articular cartilage surface as the superficial cartilage loses integrity
[51,59]. As the ECM network loses integrity, larger fissures may appear and extend into
the mid and deep zones of the cartilage [51,59,85]. In the final stages of the disease, the
articular cartilage may be worn down to the calcified cartilage, and in severe cases the
entire articular cartilage layer is lost, leaving subchondral bone in contact with the apposing
articular cartilage or bone and resulting in impaired articulation and perhaps the generation
of pain [43,51,59]. The chondrocytes in the matrix are not passive observers as the disease
progresses, and respond with a complex set of beneficial and detrimental adaptations
[43,86,87]. The anabolic response is characterized by increased production of matrix
proteins to replace lost ECM, and proliferation to form clonal sets of chondrocytes to
replace cells lost to apoptosis or necrosis and to further increase anabolic potential [43,87].
On the degenerative side, chondrocytes may respond to loss of surrounding matrix and
biomechanical changes by altering phenotype to emulate hypertrophic chondrocytes found
in the developing terminal growth plate (HZ) [87,88]. These hypertrophic chondrocytes
produce increased levels of degradative enzymes (MMP13, aggrecanases, and others) that
break down the surrounding cartilage and push the chondrocytes further down the catabolic
pathway in a positive feedback loop [87]. These changes in phenotype may also alter matrix
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production, leading to a net imbalance in anabolic to catabolic activity in the cartilage and
subsequent progression of disease [59,87].

1.3.5

Subchondral Bone in Osteoarthritis

Subchondral bone physically supports and nourishes the overlying avascular articular
cartilage [43,80]. Changes in subchondral bone properties have been long associated with
OA, most notably the occurrence of subchondral bone sclerosis and osteophyte formation
at the margin of the joint [46,80]. OA severity has also been linked to invasion of overlying
calcified cartilage by vasculature, altering nutrient and oxygen availability to the resident
chondrocytes [80,89]. Formation of bone through altered remodeling of the subchondral
bone plate and subchondral trabecular bone progresses during OA to produce a stiffer
platform for overlying articular cartilage, and some evidence shows that these changes may
precede cartilage damage in some cases [80,90]. Stiffness of the underlying bone alters the
mechanical forces experienced by the articular cartilage and may lead to cartilage loss [80].
Furthermore, bone formation may disrupt the normal congruency of the joint surface,
further altering the forces experienced by the cartilage through destabilization [75,80].
Additionally, localized regions of bone remodeling called subchondral bone cysts have
been shown to form in regions associated with cartilage degeneration, and may precede
overlying cartilage damage in certain forms of OA [46,80,91,92]. The formation of bony
osteophytes at the margin of the joint is thought to be an adaptive process to balance the
altered forces experienced by the joint as the articular cartilage thins, partially stabilizing
an imbalanced joint [80,93]. However, osteophytes may also be correlated with pain in
OA, although there is conflicting evidence of this relationship [46,94,95].
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1.3.6

Synovium in Osteoarthritis

Synovial joints are surrounded by a joint capsule that is internally lined with the synovium.
The synovium is inhabited by cells called synoviocytes that are classified as either
macrophage-like (Type A), or fibroblast-like (Type B) [44,46,96]. Macrophage-like
synoviocytes derive from a mononuclear origin and are partially responsible for the uptake
of cell debris and waste from the synovial fluid [44,46,96]. On the other hand, fibroblastlike synoviocytes stem from a mesenchymal origin, and are largely responsible for the
secretion of molecules into the synovium such as nutrients, and the lubricants hyaluronic
acid and lubricin into the synovial fluid [44,46,96]. Synovitis often appears early on in the
OA disease process and is characterized by the thickening of the synovium through
synoviocyte proliferation, increased vascularity, and infiltration by mononuclear cells [44].
Synovitis may be initiated by a release of inflammatory factors and matrix breakdown
products in the joint following an insult as seen in secondary OA, or through poorly
understood systemic and local factors in primary OA [46,75,83]. Following initiation of
synovitis, the synovium will also release inflammatory factors such as TNFα and IL-1β
that further encourage matrix destruction, leading to a positive feedback loop [44,46,83].
Synovitis has been identified in 90% of patients with OA undergoing knee and hip
replacement, and 73% of patients with knee OA assessed by MRI [44,46]. Furthermore,
synovial thickening and some synovitis biomarkers correlate well with the progression of
symptomatic OA [44,46].

1.3.7

Diagnosis of Arthritis

Diagnosis of arthritis is often reliant on the identification of symptoms by patients, who
then seek medical attention. Unfortunately, once the symptoms of pain and joint disability
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are obvious, substantial disease progression may have occurred that is currently irreversible
[43,46]. Identification of OA is often made with the use of 2D x-ray imaging of the
offending joint and examination for key bone-centered OA features including: subchondral
bone sclerosis, bony osteophyte growths, and joint space narrowing [43,46,80]. Joint space
narrowing is considered evidence of articular cartilage loss as the diminished distance
between the visible bones indicates thinning of articular cartilage that normally occupies
this area and is invisible on an x-ray scan [46,80]. New techniques utilizing magnetic
resonance imaging (MRI) with or without contrast agents are now starting to gain
acceptance, and have definite advantages over x-ray based techniques as they do not
involve the use of ionizing radiation, and can visualize the entire joint including cartilage
in 3-dimensions [46,97]. Testable biomarkers for OA detectable in blood or serum have
yet to be used reliably in a clinical setting [98,99]. However, research studies are beginning
to use biomarkers of cartilage and bone synthesis and breakdown as measures in the testing
of OA drugs and establishing pathobiology [99].

1.3.8

Treatment Methods

Currently there are no effective treatment regimens that are successful in slowing, stopping
or reversing the progression of OA once symptoms have emerged [43,46]. Instead, lifestyle
modification is often the first step in managing OA. Weight loss, reasonable exercise,
education and the use of assistive devices (ex. canes, walkers) are the first line of treatment
recommendations for individuals exhibiting symptoms of OA [46,100]. Additional
pharmacological pain and inflammation management strategies involve the use of
acetaminophen, oral or topical non-steroidal anti-inflammatories, and duloxetine [100].
Intra-articular injections of corticosteroids may also be effective in short term treatment of
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pain, but should not be considered a long term solution [100]. Alternative therapy strategies
including oral glucosamine/chondroitin, acupuncture, electrotherapy and others are not
recommended, however it is likely that they do not harm the patient so long as more reliable
strategies are also in use [100]. The use of surgical interventions is reserved for severe end
stage OA, when more moderate treatment methods have failed to relieve pain and
significant joint dysfunction [43,46,100]. Partial or complete replacement of the joint with
a prosthesis, or surgical correction of joint mal-alignment through osteotomy may be
effective in resolving joint dysfunction, however these procedures are expensive and carry
the inherent medical risks of a highly invasive surgical procedure [43,46].

1.4

The Molecular Mechanisms of Osteoarthritis

While the whole joint is involved in OA, cartilage degeneration is the classic hallmark of
the disease [43]. Chondrocytes react to a variety of stimuli both chemical and mechanical,
and respond through the anabolic formation of ECM proteins, or production of degradative
enzymes and inflammatory factors that activate catabolic activity in the surrounding tissue
[80,83,87]. While remodeling of the surrounding matrix is important for normal
maintenance of cartilage health, an imbalance in the anabolic and catabolic activity of
chondrocytes may lead to a net degenerative effect on cartilage and lead to OA [43,87].

1.4.1

Catabolic Processes

Inflammation is not typically considered a major feature of OA when compared to RA, in
which systemic inflammation plays a much more dramatic role [83,86]. However,
inflammation in the synovium (synovitis) and cartilage plays a key role in the progression
of cartilage degeneration in OA [83]. While many factors are involved, TNFα and IL-1β
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appear to be predominantly responsible for the induction of catabolic factors in cartilage
degeneration and OA [83,101]. Detectable levels of TNFα and IL-1β can be found in
samples of the synovium, synovial fluid, cartilage and subchondral bone taken from the
joints of OA patients [83]. TNFα and IL-1β induce the production of proteolytic enzymes
that break down the ECM, and encourage the release of additional inflammatory factors
including nitric oxide, prostaglandins, and interleukins-6, -17, and -18 [86]. Inflammatory
cytokines and adipokines released systemically from white adipose tissue deposits, or
locally from the fat pads located within many joints, may also influence cartilage
degeneration directly through catabolic enzyme induction, or indirectly by inducing
production of other cytokines by synoviocytes and chondrocytes [83,86,102].
Inflammatory cytokines tend to both decrease the anabolic, and increase the catabolic
activity of chondrocytes often tipping the homeostatic balance towards loss of ECM
[83,86].
Degradative enzymes are released by chondrocytes in response to chemical and physical
cues from their environment, and play an important role in physiological cartilage turnover
[49,86]. However, excessive production can lead to cartilage breakdown and diseases like
OA [59,86]. Currently, 24 mammalian MMP gene products have been identified encoding
a wide range of catabolically active enzymes [172]. Generally, MMPs are expressed as
inactive proMMPs that must be activated through disruption of a cysteine - zinc ion prodomain at the catalytic site of the enzyme [172]. Additional regulation at the level of
cellular localization further tunes MMP activity, as many of these enzymes are membrane
bound [87, 172]. Chondrocytes produce MMPs that are capable of cleaving both
collagenous and non-collagenous proteins that make up the ECM network [87]. There are
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three major types of MMPs identified in cartilage and OA: the collagenases (MMP-1, -8,
and -13), the gelatinases (MMP-2, and MMP-9), and stromelysin-1 (MMP-3) [86].
Cleavage of collagen II and aggrecan by MMP-13 appears to play a key role in OA, as
MMP-13 deficient knockout (KO) mice are protected from progression of surgically
induced OA [103]. However, while MMP-13 is often considered the primary proteolytic
enzyme of OA, areas of degraded cartilage also co-localize with MMP-1, MMP-3, and
MMP-8 and others [59,86]. Tissue inhibitor of metalloproteinases (TIMP) may counteract
some of the activity of MMPs by binding and inhibiting the active proteinases [86,104].
This is supported by the phenotype of TIMP-3 KO mice that develop OA pathology similar
to Mmp13 overexpressing mice [86,105,106].
While MMP-13 has the ability to cleave aggrecan in the cartilage ECM, a family of
proteinases collectively called aggrecanases are specialized for proteoglycan breakdown
and have been associated with cartilage degeneration in OA [86,107]. Aggrecanase-1 and
-2, also known as a disintegrin and metalloproteinase with thrombospondin motifs 4 and 5
(ADAMTS-4, -5) respectively, have been implicated as the primary aggrecanases in
cartilage [86,107]. However, genetic KO of ADAMTS-5, but not ADAMTS-4 has been
shown to attenuate cartilage degeneration following surgical induction of OA in mice,
indicating that ADAMTS-5 may be more important in driving OA related aggrecan
depletion [21,108].
Normal physiological turnover of the cartilage is important, and releases important growth
factors and other signalling factors bound to the matrix. However, breakdown of cartilage
may create a positive feedback cycle in which ECM breakdown products, or intact matrix
proteins revealed by matrix loss, can incite an inflammatory response, increasing release
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of proteinases that further increase the breakdown of the matrix [51,101]. The discoidin
domain receptor 2 (DDR2) has been shown to bind native fibrillar collagens I-III with
preferential binding for collagen II [109–111]. Breakdown of the matrix constituents
surrounding collagen II reveals binding sites for DDR2 and leads to downstream activation
of MMP-13 [109–111]. Fibronectin is a component of the ECM that when cleaved by
MMPs forms a fibronectin fragment (FN-f) that binds integrins and induces the production
of MMP-1 and -3 increasing breakdown of cartilage [63,101]. Synchronized aggrecan
cleavage by both MMPs and aggrecanases forms a 32 amino acid peptide sequence (32mer)
that signals to synovial macrophages that then release proinflammatory cytokines IL-1β
and TNFα into the joint, further potentiating cartilage breakdown [112,113]. Taken
together, these pathways demonstrate that it is important to address OA as early as possible
in the disease to prevent positive feedback loops forming from cartilage degeneration.

1.4.2

Anabolic Processes

One of the primary responsibilities of chondrocytes is the production of cartilage ECM
during development, and the maintenance of articular cartilage [87]. Growth factors are the
key class of signalling molecules that stimulate chondrocytes to produce matrix, and
proliferate [114]. Members of the TGFβ superfamily involved in cartilage anabolism and
skeletal development include: bone morphogenetic proteins (BMPs), GDF5 and TGFβ
itself [114–116]. TGFβ typically binds to a heteromeric complex made up of activin like
kinase (ALK) 5 and TGFβ-receptor-II with major downstream targets being SMAD2/3
[114,115,117]. Through this complex, TGFβ promotes chondrocyte production of ECM
proteins collagen II and aggrecan, and simultaneously down regulates the production of
matrix degrading proteinases that has a protective effect in the articular cartilage [114,115].
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However, through the SMAD2/3 pathway, TGFβ may also induce subchondral bone
remodeling, and synovial fibrosis leading to synovitis [117]. Furthermore, recent studies
indicate that TGFβ may switch to a pathogenic ALK1 dominated SMAD1/5/8 pathway in
older patients, exacerbating OA related cartilage damage through the induction of
chondrocyte hypertrophy [117,118]. BMPs tend to function similarly to TGFβ in
chondrocytes by upregulating anabolic genes [114,115]. BMP2 is upregulated in OA
chondrocytes by inflammatory molecules TNFα and IL-1β, and seems to partially
counteract the catabolic activity elicited by these cytokines [114]. Similarly, BMP7
upregulates anabolic ECM genes and partially mitigates IL-1β mediated inhibition of
proteoglycan production [114]. However, as with TGFβ, BMPs may also be involved in
OA pathogenesis as SMAD1/5/8 activation by BMPs induces chondrocyte hypertrophy
and cartilage degeneration [86,119]. Osteophyte formation induced by both TGFβ and
BMP signalling has also been correlated with OA development, further linking these
factors to the OA disease process [80,117,118].
FGF18 binds FGF receptor 3 (FGFR3) and may also increase anabolic activity in cartilage
through induction of matrix biosynthesis and chondrocyte proliferation [114,115]. In
contrast, the effect FGF2 on cartilage seems to be highly context specific, and in some
cases can lead to the initiation of chondrocyte proliferation with concomitant induction of
catabolic enzyme production, and decreased ECM biosynthesis [114,115]. On the other
hand, FGF2 has shown to be effective in vivo in cartilage defect repair, though this may be
due in part to increased proliferation of fibroblasts rather than chondrocytes [114]. Insulinlike growth factor-1 (IGF-1) binds to the IGF1 receptor (IGF1R) and plays an important
role in the maintenance of cartilage homeostasis by increasing ECM production while
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simultaneously inhibiting matrix degeneration [114,120]. While both the IGF-1 ligand and
its receptor appear to be highly expressed in OA cartilage, its effects are largely blocked
by IGF binding proteins that are also highly expressed in the same OA tissue [114].
However, it appears that IGF-1 further protects cartilage from the catabolic effects induced
by IL-1β by upregulating an IL-1 decoy receptor [114,121].

1.5

Cartilaginous Tumours

Anabolic and proliferative activity in chondrocytes may be pathogenic in some bone and
joint diseases. Cartilaginous tumors are the most common primary neoplasms found in the
skeleton [122,123]. The most common cartilaginous tumors are enchondromas that form
within the growth plate and osteochondromas that form adjacent to the growth plate
[122,123]. Following an activation event, these tumours may begin to grow and replicate
to form larger masses even in adults where the endogenous growth plate has closed
[28,122]. Transformation to chondrosarcoma generally occurs during adulthood, and while
these malignant tumours are locally aggressive, they rarely appear to metastasize [122].
Osteochondromas typically occur in the long bones in close proximity to the growth plate,
however they have been known to appear rarely in the cervical and thoracic region of the
spine [124]. Hedgehog signalling, which is important in the regulation of the growth plate,
seems to play an important role in chondroma formation [122,123]. IHH upregulates
PTHrP production in the perichondrium and inhibits terminal differentiation in the growth
plate [13,122,123]. Mutations

in

the genes

that

encode proteins

exostosin

glycosyltransferase 1 and 2 (Ext1, Ext2), which regulate heparan sulphate proteoglycan
(HSPG) synthesis, are associated with spontaneous osteochondromas, and result in
accumulation of intracellular HSPG [122,125]. HSPG in the ECM bind IHH and thus limit
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and regulate its diffusion into the perichondrium and surrounding environment [122,123].
Due to impaired HSPG transport associated with Ext1/2 mutations, abnormal hedgehog
signalling in the environment adjacent to the growth plate results in loss of polar
organization and permits the growth plate to grow partially in the wrong direction, leading
to a benign chondroma growth [122]. Interestingly, recent studies have found that deletion
of the gene Ptpn11 that encodes Src-homology 2 domain-containing phosphatase (SHP2),
a mediator of EGFR and FGFR signalling, causes metachondromatosis in mice, a disease
in which multiple enchondromas and osteochondromas form in the bone [126,127]. These
chondromas appear to form via an IHH and FGF2 dependent mechanism, somewhat similar
to Ext1/2 mutation related chondromas [122,126,127].

1.6
1.6.1

Signalling Pathways in Joint Diseases
Epidermal Growth Factor Receptor

EGFR is a member of a family of 4 receptor tyrosine kinases (EGFR or ErbB1; Her2 or
ErbB2; ErbB3; and ErbB4) located at the cell surface of chondrocytes and many other cell
types where they play a role in development, proliferation and differentiation [61,128,129].
Ligands that bind EGFR include: EGF, TGFα, amphiregulin (AR), heparin-binding EGFlike growth factor (HB-EGF), betacellulin (BTC), epigen (EPGN), and epiregulin (EREG)
[61,128,129]. These factors are initially synthesized as transmembrane proteins, and
through a process of ectodomain shedding, are proteolytically cleaved by membrane bound
metalloproteinases like a disintegrin and metalloproteinase 17 (ADAM17), releasing the
EGF-like domain into the environment [61,128,129]. Binding of ligand to EGFR induces
formation of homodimers, or heterodimers composed of the 4 EGFR family members,
followed by a transphosphorylation reaction (excluding ErbB3 which lacks kinase activity)
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and the downstream activation of a number of diverse cell signaling pathways [129].
Downstream signaling pathways include mitogen activated kinase (MAPK) cascades,
janus kinase - signal transducer and activator of transcription (JAK-STAT), Akt, and
various other protein kinase C (PKC) family proteins [129–131]. These pathways are
relatively ubiquitous to many cell types, however the overall downstream biological
responses to EGFR ligand binding are cell type- and context-specific [129,132–134].
Cellular changes in response to TGFα mediated EGFR activation include alterations in
gene expression and cell proliferation/apoptosis among other metabolic changes
[130,135,136]. Please see Fig. 1.4 for a brief synopsis of the main EGFR signalling
pathways and ligands.

1.6.2

EGFR Signaling in Osteoarthritis

The EGFR ligand TGFα has been found at increased levels in the joints of a subset of OA
patients [137]. Studies have shown that EGFR signaling is involved in the development or
protection from OA depending on the context of the OA model [130,137–142]. However,
chondrocyte phenotype loss and up-regulation of inflammatory molecules has been
observed in response to EGF using in vitro cellular and tissue culture experiments
[143,144]. We have shown that TGFα expression in cartilage is increased in a surgical
model of OA in rats (transection of the anterior cruciate ligament with partial medial
meniscectomy) [139,140]. Additional studies using ex vivo rat osteochondral explants have
indicated that TGFα induces a number of catabolic responses including the degradation of
ECM proteins collagen II and aggrecan, loss of chondrocyte phenotype and clustering, as
well as the induction of OA markers TNFα and MMP-13 [130]. Furthermore, a rat model
of surgically induced OA demonstrated decreased progression of cartilage damage when
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Figure 1.4 Epidermal growth factor receptor activation and signalling pathways.
Epidermal growth factor receptor (EGFR) is a cell surface receptor tyrosine kinase that
signals via many downstream pathways. Receptor activation is initiated by the epidermal
growth factor (EGF) family of proteins including: EGF, transforming growth factor alpha
(TGFα), amphiregulin (AR), heparin-binding EGF-like growth factor (HB-EGF),
epiregulin (EREG), betacellulin (BTC) and epigen (EPGN). These ligands are found as
transmembrane pro-forms that are proteolytically cleaved by cell surface proteases like a
disintegrin and metalloproteinase 17 (ADAM17) releasing the EGF-like domain into the
environment. Binding of ligand to EGFR causes homodimerization or heterodimerization
with other EGFR family receptors (not shown), followed by transphosphorylation of the
dimer and subsequent activation of downstream signalling. Cannonical signalling
pathways include the PLC-PKC, PI3K-AKT, Ras-Raf-MEK-ERK and Jak-Stat pathways
that induce cellular changes as indicated. Regulation of EGFR is mediated in part by Mig6, which binds to the kinase domain, blocks downstream signalling, and targets the receptor
complex for internalization. Additionally, DUSP-1 is involved in dephosphorylization and
deactivation of ERK and other MAPK proteins.

36

Figure 1.4 Epidermal growth factor receptor activation and signalling pathways

an EGFR inhibitor was used [142]. RhoA activation has been demonstrated in response to
TGFα stimulation, with following activation of rho-kinase [130]. Pharmacological
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inhibition of rho-kinase in a rat osteochondral explant model also showed a decrease in
degradation of collagen II and aggrecan by evaluation of histology with immunostained
ECM breakdown products [130]. Additionally, HB-EGF is increased in the joints of mice
with surgically induced OA, and was found to induce MMPs and inhibit aggrecan
production [64]. These experiments taken together indicate that EGFR signaling may be a
key factor in the process of cartilage degeneration in OA.

1.6.3

Negative Regulation of EGFR Signalling: Mig-6

Cell signalling feedback mechanisms exist to add an additional layer of control to
signalling pathways. The EGFR signalling pathway is under strict regulation to prevent
uncontrolled activation of the various downstream proliferative and angiogenic pathways
that may lead to the development of tumours and cancer, including osteosarcomas
[145,146]. Mitogen inducible gene 6 (Mig-6), which is also known as ERBB Receptor
Feedback Inhibitor 1 (ERRFI1), receptor associated late transducer (RALT) and Gene33
in the literature, is encoded by an immediate early response gene Errfi1 (noted as Mig-6 in
this thesis for simplicity) and has been shown to be involved in regulating overactive
signalling by EGFR (Fig. 1.4) [147]. Down regulation of Mig-6 has been identified in an
EGFR related non-small cell lung cancer, and Mig-6 appears to be involved as a tumour
suppressor in many other cancers [145,148,149]. In fact, cancer cell lines and primary lung
cancer tumours have shown mutations or polymorphisms of Mig-6 [148]. Mig-6 inhibits
EGFR signalling via two primary mechanisms. The activation of EGFR induces
downstream transcription of Mig-6, followed by production of Mig-6 protein that
subsequently binds to the kinase domain of ligand-bound EGFR, thereby inhibiting its
kinase activity and sterically blocking binding partners that facilitate signal propagation
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[150]. Mig-6 binding also targets active EGFR for desensitization by internalization with
subsequent lysosomal digestion [147,151,152]. In cell based experiments, interaction of
Mig-6 with additional factors has been identified, including: cAbl, Met, Cdc42 and 14-3-3
proteins [148]. The functional consequences of these interactions has not been clearly
demonstrated in vivo, but building evidence indicates that Mig-6 may regulate more than
EGFR signalling alone [148].

1.6.4

Mig-6 in Joint Pathology

In addition to increased susceptibility for development of lung adenomas and endometrial
cancers, two distinct global Mig-6 mouse knockout (KO) lines have shown progressive
joint diseases that result in cartilage degeneration similar to that seen in OA [149,153–156].
Down regulation of Mig-6 has also been observed in a surgical rat model of OA (partial
medial meniscectomy) where decreased Mig-6 expression followed induction of OA [157].
In contrast, studies utilizing impact induced OA models in dogs demonstrated an increase
in Mig-6 mRNA expression in degenerating cartilage [158,159].

1.6.5

DUSP-1 in Joint Pathology

Many additional factors regulate EGFR signaling both at the receptor level and through
modulation of the various downstream signaling pathways. The MEK/ERK pathway is
strongly activated by EGFR (Fig. 1.4) and has been implicated in cellular growth and
proliferation in cartilage and bone [61,115,130]. EGFR activation by TGFα has been
shown to induce activation of both the MEK/ERK and p38 MAPK [130]. Furthermore, cJun N-terminal kinases (JNKs) are also activated by EGFR signalling [160,161].
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A family of phosphatases collectively referred to as dual-specificity phosphatases (DUSPs)
or MAP kinase phosphatases (MKPs) is involved in regulating MAPK signaling. By
dephosphorylating MAPK proteins ERK, JNK, and p38, DUSP proteins attenuate
signaling by EGFR and other cell surface receptors [162,163]. DUSP-1 (also known as
MKP-1) is present in rodent cartilage and may play a role in the chondrotoxicity of certain
quinolone antibacterial agents like ofloxacin [164]. DUSP-1 may also play a role in
inflammatory rheumatoid arthritis (RA) as increased levels have been detected in
fibroblast-like synoviocytes isolated from RA patients [165]. DUSP-1 has also been shown
to be a factor in osteolysis and cartilage degeneration in inflammatory models of arthritis
[166,167]. However, little is known about the role of DUSP-1 in OA. Inhibition of
MEK/ERK signalling using in vitro and in vivo models of OA has been shown to attenuate
cartilage breakdown [130,168]. The interaction of DUSP-1 with EGFR downstream signal
regulation may play a key role in OA, and thus could be a viable therapeutic target for OA
treatment.

1.7

Animal Models in OA

Various models exist that serve to recreate the symptoms and disease process of primary
and secondary OA [108,169]. Ideally, human tissues are utilized to maximize the relevance
to the medical community. However, healthy control tissues are often difficult to obtain
due to ethical issues, and early stage OA samples are equally challenging to identify and
acquire. Furthermore, human in vivo studies are often difficult to pursue safely and
affordably. Retrospective genome wide association studies (GWAS) have been performed
to identify potential genetic factors, although due to the heterogeneity of OA, these studies
have been relatively unproductive and have identified few target genes [78,79].
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Spontaneous OA has been observed between 16 and 24 months of age in the C57BL/6
mouse strain that forms the background for many of our transgenic mice lines and is thus
heavily used to assess the role of various genes in OA [108,170,171]. Combined with ex
vivo and in vitro tissue experiments, animal models are powerful tools for evaluating the
pathogenesis of OA [108].

1.8

Overall Objectives and Hypotheses

Epidermal growth factor receptor (EGFR) signalling has been implicated in various
cancers, and plays a complex role in cartilage degeneration and osteoarthritis as shown by
our laboratory. Studies conducted both in vitro and in vivo confirm that EGFR signalling
in response to epidermal growth factor (EGF) family ligands leads to significant joint
pathology. Based on these studies, my general hypothesis is that regulation of EGFR
signalling is essential for maintenance of joint health.

1.8.1

Mig-6 in Joint Homeostasis

1.8.1.1

Objective #1

To characterize the role of Mig-6 in the maintenance of cartilage health using a cartilage
specific Mig-6 null mouse model.

1.8.1.2

Rationale #1

EGFR signalling activated by various EGF ligands leads to cartilage degeneration and
progression of osteoarthritis. Furthermore, regulation of EGFR by Mig-6 in the entire
synovial joint appears to be important in maintaining joint homeostasis, with loss leading
to joint disruption and cartilage degeneration. Utilizing cartilage-specific deletion of Mig6 in mice, I will evaluate the role of Mig-6 in maintaining cartilage health and prevention
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of osteoarthritis. These studies may provide additional mechanistic information about
osteoarthritis, and reveal new therapeutic targets for its treatment.

1.8.1.3

Hypothesis #1

Loss of Mig-6 in the cartilage of mice will result in excessive EGFR signalling and cartilage
degeneration.

1.8.2

Mig-6 in Aging and Joint Maintenance

1.8.2.1

Objective #2

To characterize the role of Mig-6 in aging cartilage, and post-natal regulation of cartilage
health.

1.8.2.2

Rationale #2

Mice with whole body deletion of Mig-6 rapidly develop joint pathology and may die
prematurely due to the secondary effects of joint immobilization, and thus long term studies
have not been conducted. Furthermore, the role of Mig-6 in post-natal cartilage isolated
from its effects during development has not been assessed. Utilizing chemically inducible
and constitutive cartilage-specific deletion of Mig-6 in mice, I will assess the role of Mig6 in regulation of homeostasis in post-natal tissue, and in elderly cartilage respectively.

1.8.2.3

Hypothesis #2

Constitutive loss of Mig-6 in cartilage will induce severe osteoarthritis in elderly mice, and
inducible deletion in post-natal tissue will lead to premature cartilage degeneration.
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1.8.3

DUSP-1 in Osteoarthritis

1.8.3.1

Objective #3

To evaluate the role of DUSP-1 in the regulation of MAPK signalling in osteoarthritis.

1.8.3.2

Rationale #3

EGFR signals via a diverse range of downstream pathways including the various mitogen
activated protein kinase (MAPK) signalling cascades. MAPK proteins have been shown to
play a role in the regulation of chondrocyte proliferation, apoptosis, and matrix production
and turnover in the maintenance of cartilage health, and in disease. Dual specificity
phosphatase 1 (DUSP-1) attenuates MAPK signalling and may play a role in regulation of
signalling downstream of EGFR in OA. Furthermore, DUSP-1 appears to be important in
regulating cartilage and bone degeneration in inflammatory arthritis. Utilizing a whole
body Dusp1 null mouse line, I will characterize the role of DUSP-1 in spontaneous age
related osteoarthritis and cartilage health.

1.8.3.3

Hypothesis #3

Dusp1 null mice will develop increased incidence and severity of spontaneous
osteoarthritis.
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Chapter 2

2

Disturbed Cartilage and Joint Homeostasis Resulting From a
Loss of Mitogen-Inducible Gene 6 in a Mouse Model of Joint
Dysfunction

This chapter has been adapted from:
Pest, M. A., Russell, B. A., Zhang, Y.-W., Jeong, J.-W., & Beier, F. (2014). Disturbed
cartilage and joint homeostasis resulting from a loss of mitogen-inducible gene 6 in a
mouse model of joint dysfunction. Arthritis & Rheumatology (Hoboken, N.J.), 66(10),
2816–27.

2.1

Abstract

Objective: Mitogen-inducible gene 6 (Mig-6) regulates epidermal growth factor receptor
(EGFR) signaling in synovial joint tissues. Whole-body knockout of the Mig6 gene in mice
has been shown to induce osteoarthritis and joint degeneration. To evaluate the role of
chondrocytes in this process, Mig-6 was conditionally deleted from Col2a1-expressing cell
types in the cartilage of mice.
Methods: Bone and cartilage in the synovial joints of cartilage-specific Mig-6-deleted
(knockout [KO]) mice and control littermates were compared. Histologic staining and
immunohistochemical analyses were used to evaluate joint pathology as well as the
expression of key extracellular matrix and regulatory proteins. Calcified tissue in synovial
joints was assessed by micro–computed tomography (micro-CT) and whole-skeleton
staining.
Results: Formation of long bones was found to be normal in KO animals. Cartilage
thickness and proteoglycan staining of articular cartilage in the knee joints of 12-week-old
KO mice were increased as compared to controls, with higher cellularity throughout the
tissue. Radiopaque chondro-osseous nodules appeared in the knees of KO animals by 12
weeks of age and progressed to calcified bone–like tissue by 36 weeks of age. Nodules
were also observed in the spine of 36-week-old animals. Erosion of bone at ligament
entheses was evident by 12 weeks of age, by both histologic and micro-CT assessment.
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Conclusion: Mig-6 expression in chondrocytes is important for the maintenance of
cartilage and joint homeostasis. Dysregulation of EGFR signaling in chondrocytes results
in anabolic activity in cartilage, but erosion of ligament entheses and the formation of
ectopic chondro-osseous nodules severely disturb joint physiology.

2.2

Introduction

Osteoarthritis (OA) is a degenerative joint disease that affects more than 10% of the adult
population of North America [1]. There are currently no clinically approved diseasemodifying treatments for OA. Consequently, patients experience a general loss in their
quality of life, with increased health care costs and lost work time causing considerable
socioeconomic damage [2]. While the precise cause and pathobiology of this disease are
not fully understood, both mechanical and genetic factors play a key role in specific
subtypes of OA [2].
The major hallmark of OA is the degeneration of the articular cartilage and the altered
phenotype or death of the only cell type in cartilage, chondrocytes [2]. Chondrocytes are
essential for maintaining articular cartilage, which is largely composed of a highly complex
network of extracellular matrix (ECM) proteins [2]. In an anabolic state, chondrocytes
produce and lay down these structural proteins into the surrounding matrix to repair
damage and build up the cartilage [2]. In a catabolic state, chondrocytes release factors to
turn

over

surrounding

cartilage

through

proteolytic

digestion

(e.g.,

matrix

metalloproteinases) and through release of cytokines (e.g., tumor necrosis factor α and
interleukin-1β), which induce catabolic activity in surrounding cells and tissues (synovium,
bone, meniscus) [2]. In healthy cartilage, anabolic and catabolic processes are in balance,
while in OA, this balance is disrupted toward a net increase in catabolic activity [2].
Bone is important in supporting the overlying cartilage but has also been implicated in the
initiation and progression of OA [3]. Both sclerosis of subchondral bone and the formation
of bony osteophyte outgrowths are common in the mid-to-late stages of OA in response to
local growth factors (such as transforming growth factor β [TGFβ] and bone
morphogenetic protein) [2]. Abnormal geometry of the bone in a joint can affect the
distribution of forces and joint stability and can lead to cartilage degeneration [4]. The

60

ligaments, tendons, and the meniscus in the knee further stabilize the joint and prevent
malalignment and overextension. Many animal models of OA exploit the stabilizing
function of the ligaments in the knee joint by using surgical techniques to reproducibly
induce a destabilized joint, with subsequent development of articular cartilage
degeneration and other OA-like phenotypes [5-8].
Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that signals through
multiple downstream pathways in a ligand- and context-specific manner [9, 10]. EGFR
ligands include epidermal growth factor (EGF), TGFα, amphiregulin, heparin-binding
EGF- like growth factor (HB-EGF), and others [11]. Evidence shows that EGFR signaling
is involved in bone and cartilage physiology during both development and homeostasis in
adulthood. EGFR signaling induced by EGF and TGFα is highly important in the regulation
of endochondral ossification during the formation of bone [9, 12-14]. We have shown that
TGFα/EGF can stimulate catabolic activity in chondrocytes in vitro and cartilage
degeneration ex vivo [15, 16]. TGFα is also up-regulated in some forms of human OA and
rheumatoid arthritis, as well as in animal models of osteoarthritis [15, 17-19]. EGFR
signaling regulates the differentiation of osteoclasts, an important cell type in the turnover
of bone [20]. Tight regulation of EGFR signaling is therefore required for the maintenance
of cartilage and bone health.
Fine tuning of EGFR signaling takes place at multiple levels, from gene transcription to
ligand binding [21]. Mitogen-inducible gene 6 (Mig-6), which is also known as ERBB
receptor–feedback inhibitor 1, receptor-associated late transducer, and Gene 33, is a
scaffold protein that binds to EGFR and impedes downstream signaling while targeting it
for internalization and degradation [22, 23]. Pathways downstream of EGFR activation
stimulate the induction of Mig6, that then acts as a negative-feedback response and
attenuates EGFR signaling [24].
Whole-body deletion of Mig6 in mice results in a complex set of phenotypes, including the
degeneration of articular joints, breakdown of articular cartilage observed at a relatively
early age, and severely diseased joints in an injury-induced model of OA [8, 25-27]. Mig6 deletion targeted to the developing mouse limb mesenchyme using the Prx1-Cre driver
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line results in the transient anabolic buildup of cartilage and the development of an OAlike phenotype with increasing age [28]. Since Mig-6 is deleted from all mesenchymal limb
tissues in these mice, it is unclear whether bone, cartilage, synovium, or multiple tissue
types acting together are involved in the development of cartilage degeneration in these
knockout (KO) models.
To evaluate the contribution of Mig-6 in the regulation of EGFR activity in cartilage
homeostasis and OA, we used a Col2a1 promoter–driven Cre/lox system to selectively
delete Mig6 from chondrocytes in mice.

2.3
2.3.1

Materials and Methods
Animals

All mice were bred and housed in accordance with the Animal Care and Use Guidelines of
Western University. To conditionally delete Mig6 in chondrocytes, Mig-6fl/fl [26, 28] mice
were bred with Col2a1-Cre mice [29-32] to generate knockout (Mig-6fl/flCol2a1-Cre+/−),
heterozygous (Mig-6fl/+Col2a1-Cre+/−), and control (Mig-6fl/flCol2a1-Cre−/− or Mig6fl/+Col2a1-Cre−/−) animals. Mice were weighed prior to killing by CO2 asphyxiation.
Genotype frequency was determined by polymerase chain reaction (PCR) analysis using
DNA processed from biopsy samples of ear tissue from mice surviving to at least 21 days
of age. Genomic excision of Mig-6 was assessed using standard PCR, with primers flanking
the loxP-flanked (floxed) region of the gene (exons 2–4) [26]. Gross morphology of the
joint was imaged using a Leica EC3 camera and a Leica S6-D microscope.

2.3.2

Skeletal Preparation and Long Bone Measurement

Animals were euthanized, skinned, and eviscerated on postnatal day 40. Overnight fixation
in 70% ethanol was followed by 2 days in acetone. Animals were stained in a solution of
0.05% alizarin red, 0.015% Alcian blue, and 5% glacial acetic acid in 70% ethanol for 10–
12 days, with clearing of extraskeletal tissues using a graded series of 2–0.5% KOH [31].
Long bones (femur, tibia, humerus, radius, and ulna) were measured using Leica
Application Suite software (v3.8.0) on images obtained using a Leica EC3 camera and a
Leica S6-D microscope.
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2.3.3

Histologic Assessment

Limbs were fixed in 4% paraformaldehyde for 24 hours and decalcified in 5% EDTA in
phosphate buffered saline (PBS), pH 7.0, for 10–12 days. Joints were processed and
embedded in paraffin in sagittal or frontal orientation, with serial sections taken at a
thickness of 5 μm. All sections were deparaffinized in xylene, rehydrated in a graded series
of 100–70% ethanol in water, followed by 100% water, and stained as follows.
Glycosaminoglycan content and general histology were assessed in sections stained with
Safranin O–fast green (0.02% fast green for 30 minutes, 1% acetic acid for 10 seconds, and
1.5% Safranin O for 3 minutes) or toluidine blue (0.04% toluidine blue in 0.2M acetate
buffer, pH 4.0, for 10 minutes). Staining of collagen content was performed using
picrosirius red (0.1% sirius red in saturated picric acid solution for 60 minutes, with 0.5%
acetic acid washes). The size and organization of collagen fibrils were determined using
polarized light microscopy [33]). Light intensity and tissue angle (45°) relative to
polarizing filter (Leica no. 11505087) and analyzer (Leica no. 11555045) were kept
identical between samples.
Following antigen retrieval and blocking with 5% serum in PBS, sections were stained
overnight at 4°C by immunohistochemistry using primary antibody for SOX9 (R&D
Systems), phospho-EGFR (phosphoTyr-1173; Cell Signaling Technology), type II
collagen (Santa Cruz Biotechnology), or proliferating cell nuclear antigen (PCNA; Cell
Signaling Technology). Sections were incubated with secondary antibody conjugated to
horseradish peroxidase (Santa Cruz Biotechnology). Following DAB+ chromogen (Dako
Canada) exposure, sections were counterstained with methyl green (0.5% methyl green in
0.1M sodium acetate buffer, pH 4.2, for 5 minutes). All sections were dehydrated in a
graded series of 70–100% ethanol in water, followed by 100% xylene, and mounted using
xylene-based mounting media. Tartrate-resistant acid phosphatase (TRAP; Sigma Canada)
staining was performed on sections of 12-week-old knee joints according to the
manufacturer's instructions, with minor alterations (i.e., 60 minutes in Triton X-100). All
images were taken with a Leica DFC295 digital camera and a Leica DM1000 microscope.
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2.3.4

Articular Cartilage Measures

Knee articular cartilage thickness and chondrocyte cell density were determined from
Safranin O–fast green–stained frontal sections by 2 observers (MAP and BAR) who were
blinded with regard to the tissue source. Leica Application Suite software (v3.8.0) was used
to evaluate the average articular cartilage thickness by measuring from the articular surface
to the subchondral bone interface across 3 points in each quadrant of the knee joint (medial
and lateral tibia and femur), in 4 sections spanning at least 500 μm. Cell density of knee
articular cartilage chondrocytes was determined by counting all lacunae with evidence of
nuclear staining in the medial femur/tibia using a centered region of interest measuring 200
μm wide and 100 μm deep from the articular surface.

2.3.5

Micro-computed Tomography (micro-CT)

Whole-body scans of 36-week-old Mig-6–KO mice were conducted using a GE eXplore
speCZT micro-CT scanner at a resolution of 50 μ/voxel. High-resolution scans of the left
knee of 12-week-old mice were conducted using a GE eXplore RS micro-CT scanner at a
resolution of 20 μ/voxel. Mice were evaluated for morphologic changes using GE
Healthcare MicroView software (v2.2) to generate 2-dimensional (2-D) maximum
intensity projection (MIP) and 3-D isosurface images [34, 35]. Abnormal tissue was
manually highlighted in red in Adobe Photoshop CC.

2.3.6

Statistical Analysis

Data are presented as the mean ± SEM. All statistical analyses were performed using
GraphPad Prism software (v6.0).

2.4
2.4.1

Results
Normal early bone development in cartilage-specific Mig-6–KO
mice

Excision of Mig-6 from the Col2a1-expressing tissues of Mig-6fl/flCol2a1-Cre+/− (KO) and
Mig-6fl/+Col2a1-Cre+/− (heterozygous) animals was confirmed using PCR amplification
for an excision-specific product (433 bp) (Fig. 2.1A). Xiphoid cartilage, meniscus, and
ectopic growths (described below) demonstrated excision of Mig-6, which was not seen
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Figure 2.1 Normal skeletal development in cartilage-specific mitogen-specific gene 6
(Mig-6)–knockout (KO) mice and control mice. A, Presence of 433-bp polymerase chain
reaction product (indicating recombination) only in joint tissues, but not control tissues
(such as the liver), from heterozygous (HET) and KO mice as compared with wild-type
(WT) control mice. Nod. = nodule (ectopic growth). B, Photograph of representative 28day-old (postnatal day 28 [P28]) female control and KO mice used in the studies. Bar = 1
cm. C, Observed (Obs.) genotype frequencies of male and female weanling (P21) mice,
showing no statistically significant difference from expected (Exp.) values (P = 0.280), by
chi-square test. D, Changes in the weights of mice from P21 to P252, showing no
statistically significant differences. E, Lengths of long bones obtained from 40-day-old
mice, showing no statistically significant differences. Values in D and E are the mean ±
SEM. F, Representative alizarin red/Alcian blue–stained skeletons of 40-day-old mice. Bar
= 1 cm. G, Alizarin red/Alcian blue–stained knee joints from 40-day-old mice, showing
normal joint morphology but abnormal staining of the tissue anterior to the meniscus
(arrow) in the KO mouse. Images are representative of 5 or more mice per group. Bar = 1
mm.
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Figure 2.1 Normal skeletal development in cartilage-specific mitogen gene 6 (Mig-6)
knockout (KO) mice and control mice
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in control liver tissue (Fig. 2.1A) or in the brain or heart (results not shown). Mig-6–KO
mice appeared outwardly normal and healthy at weaning (Fig. 2.1B). Genotype analyses
based on 644 pups in 86 litters demonstrated no evidence of embryonic or postnatal
lethality (Fig. 2.1C). The weights of animals were comparable from birth through
adulthood (Fig. 2.1D). Measurement of the femur, tibia, humerus, radius, and ulna showed
no statistically significant differences in long bone length on postnatal day 40 in female
animals (Fig. 2.1E).
Further evaluation of overall skeletal morphology by alizarin red/Alcian blue staining
showed no overt differences in the development of the axial or appendicular skeleton on
postnatal day 40 in female Mig-6–KO animals (Fig. 2.1F). Despite a lack of overall skeletal
phenotype, evidence of early ectopic growth development in knee joint tissue was seen on
postnatal day 40 in some female KO animals, as indicated by diffuse alizarin red/Alcian
blue staining of tissue from the anterior meniscus (Fig. 2.1G). The majority of male and
female KO mice developed ectopic growths in one or both knee joints, with few exceptions
(Supp. Table 2.1). Based on these data and on the similar knee joint histopathologic
features between the sexes (data not shown), females were chosen for detailed analyses for
the remainder of this study.

2.4.2

Anabolic buildup of articular cartilage in KO mice

Proteoglycan staining (Safranin O) of tissue sections appeared to be increased in the
articular cartilage of KO mice at 12 weeks, but decreased at 36 weeks (Fig. 2.2A–D).
Picrosirius red staining for collagens showed increased staining in the highly cellular areas
in the articular cartilage of KO mice (Fig. 2.2E and F). Further examination of picrosirius
red–stained sections under polarized light revealed strong red birefringence of collagen
fibers in subchondral bone, with weaker green/yellow birefringence of the articular
cartilage in control mice (Fig. 2.2G and H). Interestingly, the superficial and mid-zone
articular cartilage of KO animals tended to show more red birefringence as compared to
that in control mice, particularly at 12 weeks of age. This may indicate that the ECM
organization in these areas is altered compared to controls (Fig. 2.2G and H).
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Figure 2.2 Histologic evaluation of knee articular cartilage in 12-week-old and 36week-old cartilage-specific mitogen-specific gene 6–knockout (KO) mice and control
mice. A–D, Safranin O–fast green–stained sagittal sections of knee joints from 12-weekold (A and C) and 36-week-old (B and D) mice show large chondro-osseous nodules (nod.)
and bone infiltration (arrowhead and arrow) in the KO mice. Images in C and D are highermagnification views of the boxed areas in A and B, respectively. E–H, Picrosirius red–
stained sagittal sections of the knee joints from 12-week-old (E and G) and 36-week-old
(F and H) mice show tissue infiltrating into bone (arrowhead and arrow) in the KO mice.
Images in G and H are higher-magnification views of the boxed areas in E and F,
respectively, under polarized light. Areas between the broken lines mark superficial and
mid-zone cartilage. Images are representative of 5 mice per group. Bars = 200 μm. I, The
average thickness of the articular cartilage in the lateral femoral condyle (LFC), medial
femoral condyle (MFC), lateral tibial plateau (LTP), and medial tibial plateau (MTP) is
significantly increased in the 12 week old KO mice. J, Cell density in the medial femoral
condyle and medial tibial plateau are significantly increased in the 12 week old KO mice.
Values in I and J are the mean ± SEM. ∗∗∗ = P < 0.001; ∗∗∗∗ = P < 0.0001 by two-way
analysis of variance with Bonferroni multiple comparisons test.
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Figure 2.2 Histologic evaluation of knee articular cartilage in 12-week-old and 36-weekold cartilage-specific mitogen-specific gene 6–knockout (KO) mice and control mice.
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The thickness of the articular cartilage was increased ∼1.5-fold in Mig-6–KO mice at 12
weeks of age in all 4 quadrants of the knee joint (Fig. 2.2I). This increase in cartilage
thickness in KO mice was reduced at 36 weeks (data not shown). Cellular density was
increased in the articular cartilage of the medial tibial plateau and medial femoral condyle
of 12-week-old KO mice as compared to control mice (Fig. 2.2J). No abnormalities in cell
number, organization, or phenotype were noted in the growth plate of Mig-6–KO animals.
Immunohistochemistry for SOX9, a key regulator of chondrocyte gene expression, showed
clear nuclear staining in the expanded articular cartilage of the knee joints of 12-week-old
KO animals (Fig. 2.3A). COL2A1 staining in the superficial and mid zone of the knee
cartilage from 12-week-old KO animals was similar to that in the controls (Fig. 2.3B).
Immunohistochemical staining for phospho-EGFR (Tyr-1173) was increased in the
articular cartilage of 12- and 36-week-old KO animals (Fig. 2.3C and D), as expected upon
deletion of a negative regulator. Immunostaining for the proliferative marker PCNA in
articular cartilage was increased in 12-week-old KO animals (Supp. Fig. 2.1AB). In the
growth plate, staining for phospho-EGFR, SOX9, and PCNA (Supp. Fig. 2.1C, PCNA) in
KO animals appeared similar to that in the controls. TRAP staining for osteoclasts was
increased in the subchondral (Fig. 2.3E) and trabecular bone (Fig. 2.3F) of 12-week-old
KO animals.
Additionally, the elbow joints of 36 week old female and male KO animals also
demonstrated thickened articular cartilage (Supp. Fig. 2.2A-D), increased cellular density
(Supp. Fig. 2.2E), and SOX9 staining (Supp. Fig. 2.2F).

2.4.3

Formation of chondro-osseous nodules upon cartilage-specific
deletion of Mig-6

The formation of osteophyte-like chondro-osseous nodules in the knee joints was observed
in nearly all skeletally mature KO mice examined (Supp. Table 1). At 4 weeks of age,
knee joints from control and KO mice showed no discernible differences by micro-CT (Fig.
2.4A). However, by 12 weeks of age, all female KO mice had developed visible
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Figure 2.3 Staining for anabolic/catabolic markers in the knees of 12-week-old and
36-week-old cartilage-specific mitogen-specific gene 6–knockout (KO) mice and
control mice. Immunohistochemistry for SOX9 (A), Col2a1 (B), and phosphorylated
epidermal growth factor receptor (pEGFR; Tyr-1173) in 12-week-old animals, for pEGFR
in 36-week-old animals (D), and for tartrate-resistant acid phosphatase (TRAP) in the
subchondral (E) and trabecular (F) bone in 12-week-old animals was performed on joint
sections from control (top) and KO (bottom) mice. Images are representative of 5 mice per
group. Bars = 100 μm.
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Figure 2.3 Staining for anabolic/catabolic markers in the knees of 12-week-old and 36week-old cartilage-specific mitogen-specific gene 6–knockout (KO) mice and control
mice.
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Figure 2.4 Calcified nodules in the knee and spine of 12-week-old and 36-week-old
cartilage-specific mitogen-specific gene 6–knockout (KO) mice and control mice.
Control and KO mice were scanned by micro–computed tomography at the indicated ages.
A–C, Sagittal plane maximum-intensity projection (MIP) images (left) and 3-dimensional
isosurface images (right) obtained at age 4 weeks (A), 12 weeks (B), and 36 weeks (C),
showing ectopic calcified tissue (arrowheads and red manual contrast versus white for
bone) and bone erosion (arrow) in the KO mice. D, MIP images of 36-week-old mice. E–
G, Three-dimensional isosurface images, showing the presence of calcified material (red
manual contrast versus white for bone) in some of the 36-week-old KO animals at the base
of the skull (E), as a fusion between the C7 and T1 vertebrae (F), and between the T10 and
T11 vertebrae (G). Images are representative of 3 or more mice per group. Bars = 1 mm in
A–C and E–G; 1 cm in D.
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Figure 2.4 Calcified nodules in the knee and spine of 12-week-old and 36-week-old
cartilage-specific mitogen-specific gene 6–knockout (KO) mice and control mice
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nodules in at least 1 knee joint (Supp. Table 1 and Supp. Fig. 2.2A). These nodules
appeared as enlarged growths associated with the patella and patellar tendon (Supp.
Fig.2.2A).
By 36 weeks of age, most KO animals had developed nodules in both knees that prevented
normal ambulation (Supp. Table 1); we were unable to bend and extend these joints
harvested from KO mice, but were able to easily bend and extend the joints harvested from
control mice.
At 12 weeks of age, micro-CT analyses identified calcified tissue in the joint space of KO
mice as a diffusely radiopaque material (Fig. 2.4B). This tissue appeared to show less
intensity than bone and filled the anterior joint space and posterior areas of the joint (Fig.
2.4B). By 36 weeks, the nodules had developed an intensity similar to bone and had
integrated fully with the surrounding joint structure (Fig. 2.4C).
Further examination of similar synovial joints by micro-CT showed no evidence of
calcified tissue in the elbow, ankle, or temporomandibular joint (TMJ) (Fig. 2.4D).
However, growths along the spine were detected in multiple animals (Fig. 2.4E–G and
Supp. Fig. 2.2BC). Nodules at the base of the skull were observed in KO animals, one of
which seemed to integrate with the transverse ligament of C1 (atlas) (Fig. 2.4E). Fusion of
the C7 vertebra with the T1 vertebra was observed in 1 of the KO mice (Fig. 2.4F). Another
KO mouse developed nodules extending laterally from the transverse processes of T10 and
T11 (Fig. 2.4G).
Histologically, the nodules appeared to be composed largely of highly cellular
cartilaginous tissue at earlier time points (12 weeks) (Fig. 2.2A), staining strongly with
Safranin O. As the animals aged, histologic analysis showed a transition to a mixed
chondro-osseous tissue (36 weeks) (Fig. 2.2B and 2.5A). Examination of sections under
polarized light showed strong red birefringence in the meniscus that transitioned to less
intense birefringence in the proteoglycan-rich regions of the nodules (Fig. 2.5B). However,
calcified regions of the nodule showed strong birefringence similar to that of bone (data
not shown). Highly positive TRAP staining was observed in the areas bordering
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Figure 2.5 Histology of nodular growths in 12-week-old and 36-week-old cartilagespecific mitogen-specific gene 6–knockout (KO) mice. A, Safranin O (SafO)–fast green
stained sections of knee joints from a 36-week-old KO mouse with a nodule. Image at the
right is a higher-magnification view of the boxed area in the image at the left. B, Polarized
light microscopy [pol.] of a picrosirius red (Picro)–stained nodule (nod.) adjacent to the
anterior meniscus (menis.; delineated by the broken line) in section from a 36-week-old
KO mouse. C, Tartrate-resistant acid phosphatase (TRAP)–stained nodule in a section from
a 12-week-old KO mouse. D–G, Immunohistochemistry for SOX9 (D), Col2a1 (E), and
phosphorylated epidermal growth factor receptor (pEGFR; Tyr-1173) in nodule sections
from a 12-week-old female KO mouse and for phospho-EGFR in a nodule section from a
36-week-old female KO mouse. Images are representative of 5 mice per group. Bars = 100
μm.
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Figure 2.5 Histology of nodular growths in 12-week-old and 36-week-old cartilagespecific mitogen-specific gene 6–knockout (KO) mice.
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cartilaginous and ossified tissues in the nodular growths from the knees of 12-week-old
animals (Fig. 2.5C).
Cells composing the nodules stained strongly for SOX9 (Fig. 2.5D), COL2A1 (Fig. 2.5E),
and PCNA (Supp. Fig. 2.1D-F) at 12 weeks. Nodule cells also showed intense staining for
phospho-EGFR (Tyr-1173) at both 12 weeks (Fig. 2.5F) and 36 weeks (Fig. 2.5G).

2.4.4

Erosion of bone at ligament entheses in KO mice

Large lesions presenting as radiotransparent noncalcified or partially calcified tissue were
visible in the knee joints of Mig-6–KO mice at the age of 12 and 36 weeks, but not at the
age of 4 weeks (Fig. 2.6A–D). Histologic analysis revealed that the lesions were associated
with ligament entheses, particularly of the anterior and posterior cruciate ligaments (Fig.
2.6E). In the anterior portion of the knee joint, highly cellular, fibrocartilage-like tissue
with poor staining for glycosaminoglycan content appeared to invade the subchondral bone
via the ligament entheses and did not seem to originate from the articular cartilage (Fig.
2.2A, B, E, and F and Fig. 2.6E). Consistent with these observations, TRAP staining also
appeared to be increased in the areas of erosion associated with the ligament entheses (Fig.
2.6F). The growth plate may also be involved in nodular growths and erosion of bone, as
invading tissue was associated with a locally disrupted growth plate in severely affected
KO mice (Fig. 2.2B, E, and F).

2.5

Discussion

Data from this study suggest that disruption of Mig-6 function in mouse cartilage leads to
a complex mixture of anabolic and catabolic effects in the joints. Mig-6 has been studied
extensively for its role as a tumor suppressor in many cancers [36-38], but its role in joint
development and homeostasis is not well understood, despite the striking joint phenotypes
of mice with ubiquitous or Prx1-Cre–driven Mig-6 deletion [8, 25-28]. In the present study,
we selectively deleted Mig-6 from chondrocytes using a Col2a1-driven Cre/lox-transgenic
mouse to examine the effects of Mig6 deletion in cartilage. Based on the available
information, we believe that all or most of the described phenotype in our KO mice was
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Figure 2.6 Bone erosion in the knee joints of female 12-week-old and 36-week-old
cartilage-specific mitogen-specific gene 6–knockout (KO) mice and control mice.
Control and KO mice were scanned by micro–computed tomography at the indicated ages.
A–C, Frontal maximum intensity projection (MIP) images obtained at age 4 weeks (A), 12
weeks (B), and 36 weeks (C), showing erosions at the insertion of the cruciate ligament
(arrows) in KO mice. D, Three-dimensional isosurface images of 12-week-old control and
KO mice, showing erosion of the femur (arrowheads) in the posterior portion of the knee
joint of the KO mouse. E, Toluidine blue–stained frontal knee joint sections from 12-weekold control and KO mice, showing a subchondral cyst (asterisk), bone erosion
(arrowheads), and abnormal tissue (arrow) at the insertion of the femoral cruciate ligament
in the KO mouse. Images at the bottom are higher-magnification views of the boxed areas
in the images at the top. F, Tartrate-resistant acid phosphatase (TRAP)–stained section of
ligament enthesis from 12-week-old control and KO mice, showing increased staining in
the areas of erosion associated with the ligament entheses (arrowheads). Images are
representative of 3 mice per group in A–D and 5 mice per group in E and F. Bars = 1 mm
in A–D; 200 μm in E and F.
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Figure 2.6 Bone erosion in the knee joints of female 12-week-old and 36-week-old
cartilage-specific mitogen-specific gene 6–knockout (KO) mice and control mice.
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due to increased EGFR signaling. We cannot, however, exclude the possibility that other
cellular pathways (e.g., signaling from other receptor tyrosine kinases) contribute to some
degree.
Suppression of cellular proliferation by Mig-6 has previously been shown under multiple
experimental conditions in vitro and in vivo [39-41], for example, in keratinocytes [25-27].
Our previous work demonstrated that EGFR activation by TGFα promotes proliferation in
cultured chondrocytes [15, 18]. Here, we demonstrated an increase in cellular density in
the articular cartilage and high cellularity in chondro-osseous nodules in the cartilagespecific Mig-6–KO animals. Consistent with this finding, the increased staining for PCNA
in KO animals points to an increase in proliferation in the articular cartilage. Greater
numbers of cells expressing SOX9 and displaying EGFR activation (e.g., phospho-EGFR
staining) were present in both the articular cartilage and nodules from KO animals. An
increase in SOX9 has also been shown in response to EGFR ligands (amphiregulin, HBEGF, and others) in human urethral cancer cells [42]. Furthermore, a recent study has
demonstrated that Prx1-Cre–driven deletion of Mig-6 causes increased SOX9 and EGFR
activation in cartilage as well as increased cell proliferation in the knee joint [28], similar
to what we found in the present studies. In contrast, in our in vitro studies, TGFα was found
to decrease Sox9 expression [15, 18].
One potential explanation for these seemingly contradictory findings is that our previous
studies examined Sox9 messenger RNA levels on a per cell base, whereas here, we studied
the expression domain of SOX9 protein in tissue sections. It is therefore feasible to
speculate that the increased expression of SOX9 in our Mig-6–KO mice is secondary to
increased chondrocyte proliferation, which results from activation of EGFR signaling.
With an increase in chondrocyte number in the articular cartilage of Mig-6–KO animals,
an increase in cartilage thickness is not unexpected. Examination of picrosirius red staining
under polarized light revealed that the structure of the articular cartilage ECM in KO mice
was altered compared to that of control mice. The noncalcified articular cartilage of control
animals showed little red-orange birefringence, while that from KO animals showed
increased intensity, which may indicate a disruptive shift toward larger, organized collagen
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fibers [33]. The resultant altered stiffness of the cartilage may have an impact on the
structural integrity of the cartilage [43]. Even so, we were surprised to find that even at 36
weeks of age, the degeneration of articular cartilage from the Mig-6–KO animals was far
milder than in previously described whole-body– and limb mesenchyme–targeted KO
animals [25, 28]. Increased subchondral bone stiffness can contribute to the degeneration
of overlying cartilage by subjecting it to increased load [2, 44], and synovial tissue may
also secrete catabolic factors [2]. Normal levels of Mig-6 in the bone and other joint tissues
of our animals could explain the lack of articular cartilage damage compared to wholejoint levels in Mig-6–KO mice.
However, the difference in cartilage thickness between KO and control mice was much
less pronounced at 36 weeks than at 12 weeks. Since the superficial zone appeared to be
structurally intact (although with decreased Safranin O staining), the relative loss of
cartilage in older KO mice might be due to an advance of the tidemark and, ultimately,
replacement of cartilage by bone through endochondral ossification. This model is
supported by increased TRAP staining in subchondral bone, as well as by earlier studies
showing that TGFα/EGFR signaling in cartilage promotes RANKL expression, osteoclast
recruitment, and cartilage-to-bone transition [12, 13]. Moreover, these data suggest a
biphasic mode of EGFR/Mig-6 signaling, where it initially promotes articular cartilage
growth through chondrocyte proliferation, but ultimately causes events associated with
cartilage maturation and replacement by bone.
Loss of Mig-6 has been shown to induce the production of abnormal skeletal growths.
Whole-body KO of Mig-6 leads to the formation of osteochondral nodules in the knee,
ankle, and TMJ [25, 26]. Conditional knockout of Mig6 in the limb mesenchyme also
results in growths that have been described as central and lateral osteophytes in the knee,
although their presence in other joints was not reported [28]. In our study, targeted deletion
of Mig6 in chondrocytes resulted in the formation of chondro-osseous nodules primarily
in the knee joint. In contrast to previous findings [25, 26], we did not identify abnormal
calcified tissue in any other appendicular synovial joints or in the TMJ. Histologic analysis
also failed to show abnormal tissue in the elbows of 36-week-old Mig-6–KO animals.
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However, calcified nodular growths were identified in the spine of 36-week-old animals,
indicating that the nodule phenotype is not restricted to the knees.
In many of the Mig-6–KO animals used in this study, nodules did not form with the same
dynamics in both knees. Differences in size or complete absence of nodular formation in
one knee occurred in both sexes at 12 weeks of age. However, by 36 weeks, the nodules
had grown substantially and were present bilaterally in nearly every animal. Osteophytes,
which are similar to these nodules, commonly form as a result of surgical insult to the joint
in many rodent models [5-7], although usually not as exaggerated as in this study. Induction
of Mig-6 has been shown in canine impact models of OA [45, 46] and induction of TGFα
in rat surgical models of OA [18], demonstrating that EGFR signaling is sensitive to joint
injury and mechanical stress. This may indicate that an insult to the joint is required to
initiate the process of abnormal growth, perhaps in a dysregulated attempt to repair
localized damage.
One open question is the cellular origin of the nodules. Since cells in the nodules show
high levels of phospho-EGFR, it seems likely that they derive directly from cells in which
the Mig-6 gene has been inactivated (e.g., in which type II collagen–Cre is or was
expressed). This is further supported by the findings of our PCR analyses of genomic
recombination. While it is possible that Col2a1-Cre–mediated Mig-6 deletion during
development of the synovium may also be involved [47], the lack of nodules observed in
other synovial joints indicates that a structure specific to the knee is most likely the source
of this pathologic change. Indeed, many nodules appear to start from the meniscus that
expresses Col2a1 during its formation [48].
Novel to this study, cartilage-specific Mig-6–KO mice developed erosive lesions
surrounding ligament entheses and exhibited increased TRAP staining in the trabeculae,
subchondral bone plate, and cartilaginous tissue–ossified tissue junctions that form in the
knee nodules of KO animals. The EGFR pathway has previously been identified as a
regulator of osteoclast recruitment to developing bone as a normal component in
endochondral ossification [12-14, 20]. Diminished EGFR signaling through deletion of
TGFα or pharmacologic inhibition of EGFR results in decreased RANKL expression in
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cartilage and decreased TRAP staining in the underlying trabecular bone [12, 13, 49].
However, it is still unclear how osteoclasts would be recruited and sustained at the ligament
entheses to create the levels of damage observed at such an early age in our Mig-6–KO
animals.
Recent studies described by Staal et al [50] produced data in similar animal models that
support the results shown here. Taken together, these studies suggest that a fine balance in
EGFR signaling is required to maintain joint homeostasis. Under controlled conditions,
therapeutic agents that increase EGFR signaling may be a viable option for promoting
anabolic activity in articular cartilage. However, the complications of overstimulation of
the EGFR pathway have been demonstrated here, and additional work is required to further
elucidate this complex pathway and its effects in cartilage and joint homeostasis.
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2.7

Supplementary Tables

Supplementary Table 1: Number of Mig-6 KO and Control animals with ectopic
nodule growths in knee joints Animals were examined via dissection or through microCT
to assess the knee joints for nodules. Incidence of nodules in neither knee, a single knee
joint, or both knee joints (in a single animal) are noted.
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Supplementary Table 1: Number of Mig-6 KO and Control animals with ectopic nodule
growths in knee joints
Male
Knee Joints/animal with
nodule formation
None
Single
Both

12 Weeks
Control
KO
7
2
0
0
0
6

36 Weeks
Control
KO
4
1
0
0
0
3
Female

Knee Joints/animal with
nodule formation
None
Single
Both

12 Weeks
Control
KO
6
0
0
2
0
5

36 Weeks
Control
KO
3
0
0
0
0
3
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2.8

Supplementary Figures

Supplementary Figure 2.1 Proliferative marker PCNA is detected in Mig-6 KO
articular chondrocytes and ectopic growths.

(AB) Immunohistochemistry for

proliferative marker PCNA (brown) shows increased nuclear staining (arrowheads) in 12
weeks old KO animals (right panels) compared to Controls (left panels). (C) Growth plate
shows no difference in PCNA staining. (DE) Strong PCNA staining in (D) chondrocytelike cells, (E) chondrocyte-like and fibrotic cells of the ectopic growths in KO animals. (F)
PCNA staining of cells in the cruciate ligament entheses of KO animals. Representative
images shown. N=5. All scale bars = 20μm.
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Supplementary Figure 2.1 Proliferative marker PCNA is detected in Mig-6 KO articular
chondrocytes and ectopic growths.
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Supplementary Figure 2.2 Anabolic growth of elbow cartilage in 36 week old female
cartilage specific Mig-6 KO mice. (A) Safranin O/fast green stained sagittal sections of
the elbow joint of 36 week old Control (left) and cartilage specific Mig-6 knock out (KO)
mice (right). (B) Average cartilage thickness in the humerus, (C) radius and (D) ulna is up
to 1.6-fold thicker in both female and male KO mice. (E) Average chondrocyte density in
the humerus was increased 1.5-fold in female KO animals compared to Control. (F)
Immunohistochemistry for SOX9 shows positive staining in chondrocytes in KO animals.
Representative images shown. N=5 in all experiments. Scale bars represent 100 µm. Mean
values shown ± SEM. Data analyzed by two-way ANOVA with Bonferroni’s multiple
comparison test, ** P<0.01, ***P<0.005, ****P<0.001
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Supplementary Figure 2.2 Anabolic growth of elbow cartilage in 36 week old female
cartilage specific Mig-6 KO mice
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Supplementary Figure 2.3 Chondro-osseous nodules are visible in knee joint and
spine of female cartilage specific Mig-6 KO mice. (A) Left knee joints of female Mig-6
knock out (KO) and Control animals at 12 (left) and 36 (right) weeks of age. (B) A nodule
is visible in the lateral thoracic spine of a female KO animal. (C) Chondro-osseous nodules
are present in the spine (arrow) and knee (arrowhead), but not the ankles or elbows of a
39 week old female animal. Representative images shown. N=5, AB. N=1, C. All scale
bars = 1mm.
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Supplementary Figure 2.3 Chondro-osseous nodules are visible in knee joint and spine
of female cartilage specific Mig-6 KO mice
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Chapter 3

3

Mice with Cartilage Specific Deletion of Mig-6 Maintain
Enhanced Articular Cartilage Thickness into Late Life

These data are currently unpublished, but will contribute to an original first author research
paper to be submitted for publication:
Pest MA, Pest CA, Beier F. Mice with Cartilage Specific Deletion of Mig-6 Maintain
Enhanced Articular Cartilage Thickness into Late Life. To be submitted to Arthritis &
Rheumatology, 2015

3.1

Abstract

Background: Mig-6 acts as a negative regulator for epidermal growth factor receptor
(EGFR) signalling. Attenuation of EGFR signalling decreases osteoarthritis (OA) related
cartilage degeneration in rodent models, however, cartilage-specific Mig-6 knockout (KO)
in cartilage has been shown to induce ectopic chondro-osseous nodule formation without
significant cartilage degeneration in young mice. Conversely, whole body Mig-6 deletion
causes rapid joint degeneration. We aged cartilage-specific Mig-6 KO mice to evaluate the
long term effects of Mig-6 loss, and induced post-natal deletion of Mig-6 in mice to
evaluate the role of Mig-6 in joints beyond development.
Methods: The synovial joint tissues of the knee, ankle, and elbow were assessed in 21
month-old cartilage specific Mig-6 KO animals using histological stains, and microCT for
calcified tissue. Cartilage degeneration was scored and gait changes were also evaluated.
Post-natal deletion of Mig-6 in cartilage was induced by tamoxifen with Col2a1-CreER
mice at 3 weeks, and followed up at 12 weeks.
Results: The articular cartilage of 21 month-old Mig-6 KO animals showed increased
thickness in the knee, elbow, and ankle relative to controls. Ectopic chondro-osseous
nodules were also identified in the knee, and upper spine. Cartilage degeneration, as shown
by glycosaminoglycan (GAG) loss, was evident in the knees of 21 month-old Mig-6 KO
animals. Mig-6 Tgfa double KO mice developed similar nodules in the knee joint at 12
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weeks of age. When Mig-6 was deleted in 3 week-old animals, and followed up at 12 weeks
of age, no major changes in articular cartilage thickness or chondrocyte density were
observed.
Conclusion: Loss of Mig-6 during development causes anabolic changes in articular
cartilage that persist late into the life of mice at 21 months of age, while postnatal Mig-6
deletion produced few observable effects at 12 weeks of age. Further research is needed to
evaluate the complex role of Mig-6 and EGFR signalling in cartilage health for potential
use as a therapeutic target or in regenerative medicine.

3.2

Introduction

Degenerative joint diseases such as osteoarthritis and rheumatoid arthritis pose a serious
issue for population health in the US [1]. Costs in the form of primary health care, increased
incidence of comorbid diseases, and lost work hours are a significant burden to the
economy [1,2]. For osteoarthritis (OA), there are currently no effective means to slow or
stop the disease, and only the symptoms of joint pain and stiffness can be addressed. The
disease eventually progresses to end-stage where one of the only solutions is joint
replacement [2]. As the pathobiology of OA is poorly understood, additional research is
needed to elucidate the molecular mechanisms responsible for the initiation and
progression of joint degeneration.
Articular joints are composed of multiple different tissue types acting in concert to provide
locomotive ability and stability. Articular cartilage caps the bones of the joints, and
provides a frictionless surface for the joint surfaces to interface [3]. Subchondral bone
supports and nourishes the overlying articular cartilage. Ligaments, muscle and the menisci
in the knee prevent joint destabilization and distribute load within the joint [2]. Dysfunction
or damage to any one, or all of these tissues may be involved in OA progression, with
additional risk factors including increasing age, genetics, and obesity [2].
Articular cartilage degeneration is the accepted hallmark of OA. This layer of extracellular
matrix (ECM) rich tissue contains a limited number of chondrocytes, which are the only
resident cell type [2]. Chondrocytes are responsible for laying down ECM proteins such as
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collagen II and sulfated glycosaminoglycan (GAG) rich proteoglycan molecules (most
prominently aggrecan) into a complex network, which gives the cartilage its great elastic
flexibility and compressive strength [4]. Matrix turnover is also conducted by
chondrocytes, which produce matrix metalloproteinases (MMPs) and aggrecanases to
break down collagens and aggrecan as a part of regular maintenance in the tissue [4]. In
healthy tissue, the anabolic buildup and catabolic breakdown of cartilage ECM is in
balance. However, this may become upset by local inflammatory factors like TNFα and
IL-1β that induce excess production of catabolic enzymes, and decrease ECM protein
production [3,4]. Growth factors such as TGFβ and BMP partially oppose ECM breakdown
by increasing production of matrix proteins, however this is generally insufficient to
prevent cartilage breakdown and may contribute to the formation of bony osteophytes at
the joint margin [2].
Our lab and others have previously shown that activation of epidermal growth factor
receptor (EGFR) by its ligands epidermal growth factor (EGF), transforming growth factor
alpha (TGFα) and heparin-binding EGF-like growth factor (HB-EGF) increases cartilage
degeneration in vitro and in vivo, and that attenuation of EGFR signalling partially protects
animals from progression of surgically induced osteoarthritis [5–9]. However, recent work
has revealed that genetic deletion of Mig-6, which encodes the protein Mig-6 that acts as a
negative regulator of EGFR signalling, may induce formation of thicker articular cartilage,
ectopic chondro-osseous nodules, and increased chondrocyte proliferation [10–13]. Mig-6
is encoded by an immediate early response gene (Errfi1, denoted Mig-6 in this text for
simplicity) and targets ligand-bound EGFR for internalization, lysosomal degradation, and
further blocks receptor transactivation [14]. Beyond its role as a negative-feedback sensor
for EGFR, in the absence of EGFR ligands Mig-6 also appears to interact with c-Abl and
may be involved in cellular apoptosis [15]. Mice with whole body, or limb mesenchymespecific deletion of Mig-6 initially show increased articular cartilage thickness, however,
within a few months of life they begin to show early signs of cartilage degeneration similar
to osteoarthritis, the mechanism for which is still unclear [12,13,16,17]. Conversely, mice
with cartilage-specific deletion of Mig-6 appear to develop thicker articular cartilage in the
knee that is maintained into adulthood [10,11]. Further research is required to evaluate the
role of Mig-6 and EGFR signalling in the anabolic maintenance and development of
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articular cartilage, for possible use as a therapeutic target in OA and other degenerative
diseases of cartilage.
In this study, we aged mice with cartilage-specific deletion of Mig-6 to 21 months of age
to evaluate the role of Mig-6 in cartilage homeostasis and OA development. Additionally,
Mig-6 deletion in chondrocytes was conditionally induced in three week-old mice to
assess the role of Mig-6 in postnatal cartilage tissue.

3.3
3.3.1

Methods
Animals

All mice used in this study were bred and housed in accordance with the Animal Care and
Use Guidelines of Western University – Canada. Mice were weighed prior to sacrifice by
CO2 asphyxiation. As previously described [10], Mig-6 (gene Errfi1, denoted as Mig-6 for
simplicity) was conditionally deleted in chondrocytes through breeding Mig-6fl/fl [16] to
Col2a1-Cre+/- [18] mice creating knockout (KO, Mig-6fl/flCol2a1-Cre+/-) and control (Mig6fl/flCol2a1-Cre-/- or Mig-6fl/+Col2a1-Cre-/-) mice (Fig. 3.1A). Only female mice were
examined for 21 month and 4 week (supplementary data) time points. Additional
experiments utilized mice bearing either the ROSA26mTmG reporter gene [19] or Tgfa null
(encodes TGFα cytokine) mice [20] in concert with Mig-6fl/fl and Col2a1-Cre+/- to evaluate
cell fate within the articular cartilage and ectopic nodules, and the role of TGFα in ectopic
tissue formation respectively.
Post-natal conditional deletion of Mig-6 utilized the same ‘floxed’ Mig-6 line above, bred
to a tamoxifen inducible Col2a1-CreERT2 [21] line of mice to produce CreER(+) [Mig6fl/flCol2a1-Cre+/-] and CreER(-) [Mig-6fl/flCol2a1-Cre-/-] mice (Fig. 3.1B). One additional
trial consisted of CreER animals that were heterozygous for the ROSA26mTmG reporter gene
[19] to evaluate tamoxifen induced Cre activation in articular cartilage chondrocytes. Male
mice were used for tamoxifen experiments. Genotyping and assessment of genomic
recombination was performed on DNA samples processed from ear and xyphoid cartilage
tissue biopsies. Standard PCR was performed using primers on either side of, and within
the ‘floxed’ Mig-6 allele (Mig-6 exons 2-4 flanked by loxP sites) to amplify products of
the recombined or intact gene [10,16].
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Figure 3.1 Experimental design and evaluation of joints. (A) Cartilage specific Mig-6
knockout (KO, Mig-6fl/fl;Col2-Cre) and control mice (Mig-6fl/fl or Mig-6fl/+) were aged to
21 months to evaluate synovial joint integrity and osteoarthritis. (B) Inducible cartilage
specific Mig-6 KO mice (Mig-6fl/fl;Col2-CreER) were injected at 3 weeks of age with 5
courses of tamoxifen or vehicle over 5 days. Mice were then aged to 12 weeks of age before
sacrifice. (C) Diagrams of the knee, elbow and ankle joint evaluated in this study.
Approximate areas of articular cartilage measurements are indicated by dashed red lines.
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Figure 3.1 Experimental design and evaluation of joints
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3.3.2

Post-natal induction of recombination

Mig-6 recombination and resultant deletion in 3 week old CreER(+) male mice was induced
by intraperitoneal injection of 75 mg/kg tamoxifen dissolved in sterile corn oil delivered in
5 doses over 5 days (Fig. 3.1B). CreER(-) mice were used as controls, with additional
controls using sterile corn oil vehicle delivered to CreER(+) and CreER(-) mice. Following
the final course of tamoxifen, mice were housed for 5 days in an inclusion facility and then
transferred to general housing until sacrifice at 12 weeks of age.

3.3.3

Histology

The knee, elbow, and ankle joints of mice were taken and fixed in 4% paraformaldehyde
in phosphate buffered saline (PBS, pH 7.0) for 24 hours at room temperature. The intact
joints were then decalcified in 5% ethylenediaminetetraacetic acid (EDTA) in PBS (pH
7.0) for 10 – 12 days at room temperature. All joints were processed for paraffin
embedding, and 5 µm thick serial sections were taken in the sagittal or frontal orientation
as indicated. Sections were stained with either toluidine blue (representative images
shown) or safranin O/fast green to evaluate glycosaminoglycan (GAG) staining, and
structural changes in the joints, as previously described [10]. Immunostaining was
performed using anti-GFP antibody (Cell Signalling) and protocols previously described
[10]. Images were taken using a Leica DM1000 microscope with attached Leica DFC295
camera, or a Leica DMRA2 fluorescence microscope (supplementary data).

3.3.4

Micro-computed Tomography (microCT)

Scans of the whole animal were taken at 21 months of age to examine skeletal morphology
in detail. A GE eXplore speCZT microCT machine was used to take scans at a resolution
of 50 µm/voxel, as before [10]. The mice were assessed for skeletal pathology and general
morphological abnormalities using GE Healthcare MicroView software (v2.2) to generate
both 2D maximum intensity projection (MIP) images and 3D isosurface renderings [10,22].

3.3.5

Articular Cartilage Thickness and Degeneration

The average thickness of the articular cartilage surfaces of the joints in the knee, elbow,
and ankle were taken at 3 locations evenly spaced over the articulating surface being
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examined (Fig. 3.1C). Measurements were made from the osteochondral junction to the
intact surface of the articular cartilage. Slides were examined at 6 regularly spaced points
over 500 µm for the knee in the frontal orientation, and the ankle and elbow in the sagittal
orientation [10]. As the talus in the ankle interfaces with at least 3 separate bones in the
orientation examined, the individual interfacing surfaces were measured separately (Fig.
3.1C). Blinded examination of the articular cartilage for signs of OA-like degeneration was
performed by a single scorer (MP) using the OARSI recommendations for cartilage
degeneration scoring in mice [23,24].

3.3.6

CatWalk Gait Analysis

The Noldus CatWalk system (v7.1) was utilized to assess changes in walking gait. Briefly,
the animal’s steps are registered as it walks along a glass plate that is imaged by a camera
from below and interpreted by the accompanying software as a set of gait parameters [25].
We assessed the rear limb duty cycle (% of time in stand phase of walk cycle) and stride
length in age matched 21 month old mice.

3.3.7

Statistical Analysis

All graphical data are presented as the mean ± SEM. Statistical analysis was performed
using GraphPad Prism software (v6.0), with two-way ANOVA with Bonferroni's multiple
comparisons test, or t-tests presented as appropriate.

3.4
3.4.1

Results
Mig-6 KO animals are relatively healthy

Female Mig-6 KO mice aged to 21 months appeared to be generally healthy, despite knee
and spine pathology discussed below. While male animals were not examined in this
experiment, our previous work has shown very similar phenotypes between sexes up to 36
weeks of age [10]. A single KO animal out of 5 died of unknown causes prior to 21 months
of age. Mig-6 KO mice aged to 21 months trended towards being slightly heavier than
control animals (Supp. Fig. 3.1A).
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3.4.2

Calcified nodule formation in 21 month-old Mig-6 KO mice is
restricted to knee joint and upper spine

In Mig-6 KO mice aged to 21 months, we observed extensive development of ectopic
chondro-osseous nodules primarily in the knee joint, and cervical spine with additional
nodules sporadically in the thoracic region of the spine (Fig. 3.2, red arrows). We were
unable to locate further calcified nodules in any other joints examined, however noncalcified growths are not detectable using microCT and may be present in areas not
histologically examined in detail.
In the cervical spine, calcified tissue was found within the neural canal of the first cervical
vertebra (C1, atlas) at the base of the skull of all Mig-6 KO animals examined, but none of
the controls (Fig. 3.3A). This calcified tissue is most likely associated with the transverse
ligament of the atlas based on its location. Additional calcified nodules were identified
surrounding the superior/inferior and transverse costal facets for the ribs in the thoracic
spine (Fig. 3.3B). All Mig-6 KO animals demonstrated at least 2 of these nodules within
the thoracic spine, but not necessarily at the same vertebral levels. Toluidine blue stained
sagittal sections of the spine show masses similar in appearance nodules in the knee joint
(below), with pockets of strong GAG stained cartilaginous tissue, bordered by bone-like
tissue (Fig. 3.3B). Due to difficulties in sectioning, only a small number of these nodules
were captured in histology.
Toluidine blue stained sagittal sections of the knee reveal large, invasive tissue growths in
the anterior and posterior region of the joint, composed of large pockets of GAG-rich
cartilage-like tissue adjacent to the endogenous articular cartilage surface and integrating
with the menisci (Fig. 3.4A, dark blue/purple stain). The tissue extends anteriorly from the
meniscus and fills the joint space, follows the patellar ligament, and invades the tibia at the
patellar ligament enthesis, disrupting the tibia growth plate (Fig. 3.4A, red asterisk). What
appear to be marrow pockets (Fig. 3.4A, red arrows) are surrounded by bone-like, or
fibrous tissue. Calcified tissue was examined using microCT, and further confirms that the
bone-like tissue in Mig-6 KO animals is calcified, and fully integrates into the underlying
bone, effectively immobilizing the joint (Fig. 3.4B). Furthermore, the anterior and
posterior cruciate ligaments (ACL/PCL) of Mig-6 KO animals appeared to show cartilage
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Figure 3.2 Extensive formation of chondro-osseous nodules in the knees and spine of
21 month old cartilage specific Mig-6 KO mice. Representative 3D isosurface rendering
from 50 µm/voxel microCT scans of the whole skeleton of control (top) and KO (bottom)
mice. Areas of ectopic nodule development are indicated (red arrowheads) in the knee,
and upper spine. Scale bar = 10 mm. N = 3.
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Figure 3.2 Extensive formation of chondro-osseous nodules in the knees and spine of 21
month old cartilage specific Mig-6 KO mice.
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Figure 3.3 Ectopic chondro-osseous tissue forms at the base of the skull and the rib
joints of 21 month old Mig-6 KO mice. (A) Representative 2D maximum intensity
projection (MIP) image of the base of the skull and cervical spine (C1-5) of control (left)
and Mig-6 KO mice (right). A calcified mass is present in the region associated with the
transverse ligament of the atlas (C1, yellow arrowhead). Scale bar = 2 mm. N=3. (B)
Representative toluidine blue stained sagittal section of the thoracic spine shows a costal
facet (CF) and rib head (RH) of a control (left) and KO (right) animal. A large chondroosseous nodule (Nod) is present and integrates the two bones. Scale bar = 200 µm. N = 3
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Figure 3.3 Ectopic chondro-osseous tissue forms at the base of the skull and the rib
joints of 21 month old Mig-6 KO mice.
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Figure 3.4 Ectopic chondro-osseous nodules form in the knee of 21 month old Mig-6
KO mice. (A) Representative toluidine blue stained knee section are shown in the sagittal
plane of Mig-6 KO (bottom) and control (top) animals. Mixed tissue chondro-osseous
ectopic nodule growths (Nod) are present in the anterior and posterior region of the joint.
F = femur, T = tibia. Scale bar = 1 mm. N=3. (B) Representative 2D MIP images of the
knee of control (bottom) and KO (top) mice. Scale bar = 1 mm. (C) Representative
toluidine blue stained section of the knee joint in the frontal orientation shows cartilage
neo-genesis (yellow asterisks) in the anterior and posterior cruciate ligaments (ACL/PCL)
of Mig-6 KO (bottom), but not control (top) mice. Scale bar = 200 µm. N = 3.
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Figure 3.4 Ectopic chondro-osseous nodules form in the knee of 21 month old Mig-6 KO
mice
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neogenesis along their length, with bone erosion associated with the femoral and tibial
ligament entheses (Fig. 3.4C, 3.6A, yellow asterisks), and further localized disruption of
the growth plate (Fig. 3.6A, red arrowhead). Nodules were visible upon dissection of 21
month-old Mig-6 KO knee joints as a mass of tissue notably disrupting the patellar ligament
(Supp. Fig. 3.2A, red asterisk). Interestingly, 4 week-old Mig-6 KO mice did not show
any visible signs of nodule formation in the knee or ankle by histological examination,
indicating ectopic tissue is not present at birth (Supp. Fig. 3.3AB).

3.4.3

Ectopic nodules are composed of cells that express Cre

To assess whether ectopic nodules form from Mig-6 KO cells in a cell-autonomous fashion,
we utilized the ROSA26mTmG reporter line and 3 imaging techniques to evaluate 5 monthold male age-matched Mig-6 KO ROSA26mTmG reporter mice (n=1 per imaging modality,
total n=3). Red fluorescent protein (RFP) is constitutively expressed in all cells until
deactivated by Cre recombination, coupled to activation of green fluorescent protein (GFP)
expression [19]. Fluorescence imaging using a stereo microscope revealed green
fluorescence in the nodule tissue of a disarticulated Mig-6 KO knee joint (Supp. Fig. 3.4A,
black asterisk). Similar imaging techniques using progressive whole animal
cryosectioning and fluorescence imaging (CryoViz, Bioinvison [26]) showed GFP
fluorescence in the ectopic nodules (black asterisks), and articular cartilage of a Mig-6
KO mouse (Supp. Fig. 3.4B). Similarly, histology shows a large proportion of the cells in
the ectopic growths adjacent to the meniscus are no longer expressing RFP, and seem to
be expressing GFP (Supp. Fig. 3.4C). Taken together, these data indicate that the ectopic
growths in the knees of Mig-6 KO animals are derived from cells that have expressed Cre
recombinase protein and are likely deficient in Mig-6.

3.4.4

TGFα is not required for ectopic nodule formation in Mig-6 KO
mice

TGFα is present in the knee joint and is important during bone and joint development [27].
We mated Tgfa null mice to Mig-6 KO animals to assess the role of TGFα in the
development of ectopic nodules in the knee joint. Cartilage-specific Mig-6 KO mice (N=1
male, N=2 female) developed similar ectopic growths in the absence of TGFα at 12 weeks
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Figure 3.5 Loss of TGFα does not protect 12 week old cartilage specific Mig-6 KO
mice from ectopic tissue formation in the knee. Mice with whole body deletion of Tgfa
were bred with Mig-6fl/flCol2a1-Cre mice to create double KO animals. Representative
toluidine blue stained sagittal knee sections show similar nodule formation (yellow
asterisk) and growth plate disruption (red arrows) in Tgfa null Mig-6 KO mice and control
Tgfa wild type Mig-6 KO mice. Cre negative controls did not develop ectopic tissue. F =
femur, T = tibia. Scale bar = 200 µm. N = 1 male, 2 female.
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Figure 3.5 Loss of TGFα does not protect 12 week old cartilage specific Mig-6 KO mice
from ectopic tissue formation in the knee
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of age (Fig. 3.5, yellow asterisks), suggesting that TGFα is not required for the formation
of these growths.

3.4.5

Thicker articular cartilage is present in multiple joints of 21 month
old Mig-6 KO

The role of Mig-6 in cartilage anabolism in 21 month old mice was examined by measuring
the thickness of the articular cartilage from the subchondral bone to the intact cartilage
surface of the knee, ankle, and elbow joints (Fig. 3.1C).
Frontally oriented toluidine blue stained sections of the knee show slightly weaker GAG
staining in the expanded non-calcified articular cartilage relative to control animals (Fig.
3.6A). The surface of the articular cartilage in KO animals does not show extensive
fibrillation, and is relatively smooth and continuous (Fig. 3.6A, inset). However, the
contour of the joint in KO shows unusual hills and valleys typically in areas adjacent to
cartilage-like masses in the ligaments or meniscus that may impinge on the articular
cartilage surface (Fig. 3.6A, dashed red line LFC). The articular cartilage thickness was
increased in the lateral femoral condyle (LFC) and medial femoral condyle (MFC) of KO
animals, with a further trend towards an increase in the lateral tibial plateau (LTP) (Fig.
3.6B). However, the medial tibial plateau (MTP) showed no large differences (Fig. 3.6B).
To evaluate cartilage degeneration within the knee, 6 sections spanning at least 500 µm
were evaluated and degeneration scores summed across the depth of the quadrant based on
OARSI cartilage degeneration scoring guidelines [23,24]. OARSI scoring demonstrated a
non-significant increase in cartilage degeneration in KO animals in the LTP, MFC, and
MTP with a clear increase in degeneration observed in the LFC relative to controls (Fig.
3.6C). The total joint score (sum of LFC/LTP/MFC/MTP) was significantly higher in the
KO animals compared to controls (Fig. 3.6C). The majority of damage observed was
related to localized loss of GAG staining, with little disruption of the underlying cartilage
structure with the exception of one KO animal that showed signs of matrix loss (Fig 3.5C).
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Figure 3.6 Articular cartilage thickness is enhanced in the knee joints of 21 month old
cartilage specific Mig-6 KO mice. (A) Representative images of toluidine blue stained
frontally sectioned knees of control (left) and Mig-6 KO (right) mice. A magnified view of
the articular cartilage surface shows a relatively smooth surface in KO mice (Inset).
Cartilage neogenesis (yellow asterisk) in the ACL/PCL of KO animals. The joint contour
is disrupted in KO mice (red dashed line). Local disruption of the growth plate (red
arrowhead) is also present. LFC = lateral femoral condyle, LTP = lateral tibial plateau,
MFC = medial femoral condyle, MTP = medial tibial plateau. Scale bars = 200 µm. N=3.
(B) Measured articular cartilage thickness from subchondral bone to intact cartilage
surface, see Fig. 3.1. for details on measurements. Articular cartilage thickness is enhanced
in the LFC and MFC of Mig-6 KO mice. (C) Articular cartilage degeneration scores based
on OARSI recommendations [23]. Mig-6 KO mice show increased cartilage degeneration
in the LFC and Total Joint. The majority of scores consisted of GAG depletion without
matrix breakdown. (A-C) Individual data points presented with mean ± SEM. Data
analyzed by two-way ANOVA with Bonferroni's multiple comparisons test, * p < 0.05,
*** p < 0.005, **** p < 0.001. N = 3.
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Figure 3.6 Articular cartilage thickness is enhanced in the knee joints of 21 month old
cartilage specific Mig-6 KO mice
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The gait patterns of 21 month old control and Mig-6 KO mice (N=4, age matched) were
examined immediately prior to sacrifice. The duty cycle (% time in stand phase of walk
cycle) of the hind limbs showed a non-significant decrease in KO animals relative to
controls (Supp. Fig. 3.5A). No statistically significant differences were noted in the rear
limb stride length of Mig-6 KO mice (Supp. Fig. 3.5B).
The ankle was then examined to evaluate a joint that does not show any apparent formation
of chondro-osseous nodules, which may influence degeneration through increased joint
imbalance and abnormal loading [2,28]. We evaluated a number of joint interfaces
(notation: Measured surface –opposite interfacing surface, ex. Tibia-talus), as some bones
have multiple joint surfaces (Fig. 3.1C). The joint surfaces of the talus (Tal), navicular
(Nav) and calcaneus (Calc) all showed increased articular cartilage thickness (30-100%) in
KO animals, in contrast to the tibia (Tib) (Fig. 3.7AC). The GAG staining in the noncalcified articular cartilage also appeared more intense in Mig-6 KO mice, indicating there
may be increased proteoglycan content (Fig. 3.7A). No evidence for degeneration was
seen in ankle joints of any animal examined. Similar findings are seen in the ankle of 4
week old Mig-6 KO mice, with statistically significant increases in the talus-navicular joint,
and non-significant increases the talus-calcaneus, and talus portion of the tibia-talus joint
(Supp. Fig. 3.3BC). Intermediate increased articular cartilage thickness in 4 week old Mig6 KO mice may indicate increased cartilage expansion relative to their control littermates
as the animals grow.
The elbow joint also appears unaffected by nodules in KO animals based on microCT
analysis (Fig. 3.2) and histology (Fig. 3.7B). Measurements of the radius, ulna, and
humerus in KO animals show an increase (≥100%) in the thickness of the articular cartilage
relative to control animals (Fig. 3.7D). The thickened articular cartilage in KO animals
stained robustly for GAG, particularly when compared to control animals (Fig. 3.7B).
Interestingly, in each Mig-6 KO animal we also observed what may be cartilage neogenesis extending proximally from the distal humerus (trochlea of the humerus) into the
olecranon fossa and coronoid/radial fossa (Fig. 3.7B, black arrowheads).
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Figure 3.7 Articular cartilage thickness is enhanced in the ankle, and elbow of 21
month old cartilage specific Mig-6 KO mice. (A) Representative toluidine blue stained
sagittal ankle sections of control (left) and Mig-6 KO (right) mice. T = tibia, Ta = talus, N
= navicular, C = calcaneus. (B) Representative toluidine blue stained sections of sagittal
elbows of control (left) and Mig-6 KO (right) mice. Evidence of cartilage neogenesis
(black arrows). H = humerus, R = radius, U = ulna. (C) Ankle articular cartilage thickness
was increased in Mig-6 KO mice in all joint interfaces examined excluding the tibia of the
tibiotalar joint (Tib-tal). (D) Elbow articular cartilage thickness was significantly increased
in Mig-6 KO mice in all joint surfaces examined. (A-C) Individual data points presented
with mean ± SEM. Data analyzed by two-way ANOVA with Bonferroni's multiple
comparisons test, * p < 0.05, ** p < 0.01, *** p < 0.005, **** p < 0.001. All scale bars =
200 µm. N = 3.
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Figure 3.7 Articular cartilage thickness is enhanced in the ankle, and elbow of 21 month
old cartilage specific Mig-6 KO mice
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3.4.6

Post-natal induction of Mig-6 deletion targets a subpopulation of
articular chondrocytes

To evaluate the role of Mig-6 in postnatal cartilage, we induced Cre activity at 3 weeks of
age using mice with tamoxifen inducible Col2a1-CreER and conditional deletion Mig-6fl/fl
alleles [16,21]. Mice positive and negative for CreER received either tamoxifen or vehicle
in 5 injections over 5 days to adequately induce recombination (Fig. 3.1B). We assessed
tamoxifen-induced, Cre-mediated deletion of Mig-6 by examining PCR products for
recombination (or the intact allele) with two primers flanking the ‘floxed’ region and one
within. Only the ear and xyphoid cartilage of CreER(+)/Mig-6fl/fl animals injected with
tamoxifen showed the presence of the recombined (deleted) Mig-6 allele (Supp. Fig.
3.6A). The intact band is still present in these animals, indicating either that the
recombination efficiency is not 100% or contaminating tissue was present. A single
additional trial was conducted with animals bearing the ROSA26 targeted mTmG reporter
discussed above [19]. Immunostaining of sections of the knee joint indicate the presence
of GFP expression in chondrocytes in at least 2 regions of the tibia of a CreER(+)/Mig-6fl/fl
tamoxifen injected animal, but not in controls (Supp. Fig. 3.6B). This would indicate that
at least a subpopulation of chondrocytes is undergoing recombination, however the
regional variability within the same joint of the animal examined does raise concerns
regarding recombination efficiency. Additional trials need to be performed to confirm
adequate deletion of Mig-6 in these animals.
However, induction of Cre activity in CreER mice with tamoxifen at 3 weeks and aging to
12 weeks did not seem to cause any general health concerns. Male CreER mice did not
show any trends or statistically significant differences in weight after tamoxifen injection
(Supp. Fig. 3.1B). Female animals were not examined in tamoxifen induced CreER
experiments to reduce potential systemic effects of tamoxifen and female hormones.

3.4.7

Post-natal induction of Mig-6 deletion increases lateral tibia
articular cartilage thickness

We examined the thickness of knee articular cartilage thickness as described above (Fig.
3.1C). Only the LTP quadrant of the knee showed a statistically significant increase in
cartilage thickness for tamoxifen injected CreER(+) mice relative to vehicle, but not the
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tamoxifen injected CreER(-) controls (Fig. 3.8AB). No observable effects on the growth
plate, menisci, or anterior/posterior cruciate ligaments were noted (Fig. 3.8A).
Furthermore, animals did not demonstrate any evidence of nodule formation in the knee
during a gross evaluation of knee morphology during dissection (Supp. Fig. 3.2B). The
number of chondrocytes in a defined region (200 µm x 100 µm box) of the MTP was
examined to evaluate chondrocyte proliferation following post-natal Mig-6 deletion. No
statistically significant differences were observed in tamoxifen injected CreER(+) animals
when compared to any control groups (Fig. 3.8C).
Following the knee, we examined the elbow joint of CreER animals, since 21 month-old
KO mice showed the largest increase in cartilage thickness in this joint. The elbow of
tamoxifen injected CreER(+) mice did not show thicker articular cartilage in the humerus,
ulna, or radius when compared to control groups (Fig. 3.9AB). Furthermore, GAG staining
appeared similar between groups (Fig. 3.9A).

3.5

Discussion

In this study we demonstrated that at 21 months of age, mice with cartilage-specific
deletion of Mig-6 develop partially calcified chondro-osseous nodules in the knee and
spine, and furthermore show increased articular cartilage thickness with a minor increase
in cartilage degeneration in the knee. We also demonstrated that post-natal deletion of Mig6 at 3 weeks of age was insufficient to induce similar cartilage anabolism when examined
9 weeks later in mice 12 weeks of age.
These findings complement previous studies that examined Mig-6 and EGFR in mouse
joints using various models. Whole body deletion of Mig-6 first demonstrated that Mig-6
plays an important role in homeostasis of joint tissues, with animals rapidly developing
debilitating joint nodules in the knee, ankle and temporo-mandibular joint (TMJ) and
cartilage degeneration in the knee [16,17]. The majority of these animals died by 3 months
of age due to difficulty feeding with TMJ impairment. This was resolved in a study that
used a Prx-1 driven Cre to delete Mig-6 in the limb mesenchyme and resultant whole joint,
first demonstrating a transient anabolic effect in the knee that gave way to cartilage
degeneration by 16 weeks of age [12]. Use of two different but functionally similar Col2a1-
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Figure 3.8. Post-natal deletion of Mig-6 at 3 weeks mildly increased articular cartilage
thickness in the knee of 12 week old mice. (A) Representative images of toluidine blue
stained frontal knee sections of tamoxifen (bottom) and vehicle (corn oil, top) injected,
Col2-CreER(-) [left] and Col2-CreER(+) [right] 12 week old mice. LFC = lateral femoral
condyle, LTP = lateral tibial plateau, MFC = medial femoral condyle, MTP = medial tibial
plateau. (B) Articular cartilage thickness was increased only in the LTP of tamoxifen
injected CreER(+) mice relative to vehicle controls. (C) Number of chondrocytes in the
articular cartilage of the MTP did not increase in tamoxifen injected CreER(+) mice or
controls. (A-C) Individual data point presented with mean ± SEM. Data analyzed by twoway or one-way ANOVA with Bonferroni's multiple comparisons test, **p < 0.01. Scale
bar = 200 µm. N ≥ 4.
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Figure 3.8 Post-natal deletion of Mig-6 at 3 weeks mildly increased articular cartilage
thickness in the knee of 12 week old mice.
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Figure 3.9. Post-natal deletion of Mig-6 at 3 weeks did not increase the articular
cartilage thickness in the elbow of 12 week old mice. (A) Representative toluidine blue
stained sagittal elbow sections of tamoxifen (bottom) and vehicle (corn oil, top) injected,
Col2-CreER(-) [left] and Col2-CreER(+) [right] 12 week old mice. H = humerus, R =
radius, U = ulna. Scale bar = 200 µm. (B) Articular cartilage thickness was not increased
for any joint surface examined. Individual data point presented with mean ± SEM. N ≥ 4.
Data analyzed by two-way ANOVA with Bonferroni's multiple comparisons test
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Figure 3.9 Post-natal deletion of Mig-6 at 3 weeks did not increase the articular cartilage
thickness in the elbow of 12 week old mice
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Cre driver mice further restricted Mig-6 deletion to cartilaginous tissues, and demonstrated
that the thickened articular cartilage in Mig-6 KO mice persisted until 36 weeks and 15
months of age, although these animals still developed ectopic growths in the knee joint
[10,11].
The role of EGFR signalling and Mig-6 in human musculoskeletal diseases is not entirely
clear. However, mutations in EGFR and Mig-6 have been repeatedly implicated in lung
cancer [29,30] and EGFR signalling may be involved in the formation of various types of
sarcomas [31,32]. The phenotype we have described here, and previously [10], resembles
the pathology associated with chondromatosis and exostosis in which cartilaginous
extensions form from the bone or joint, and progressively ossify [33–35]. Studies have
shown that Ptpn11 (SHP2), which facilitates EGFR signaling, is involved in the regulation
growth of cartilage and bone and that loss of SHP2 results in metachondromatosis in the
ankle and knee [36–38]. However in these studies, loss of SHP2 generally decreased
downstream signalling to MEK/ERK, which is converse to the effects of loss of Mig-6, as
previously observed [10–13,16]. Considering this, it is possible that the Mig-6 KO
phenotypes observed are not entirely due to EGFR modulation and may be partially
mediated by interactions with other receptor tyrosine kinase proteins like MET, proteinprotein interactions with c-Abl, or others [15,39]. On the other hand, Exostosin 1 and 2
(EXT1/2) are important in the synthesis of heparan sulfate (HS) GAG chains, and partial
or complete loss of Ext1 has been associated with both hereditary and spontaneous
osteochondromas, similar in structure to the nodules we have described [35,40,41].
Heparan sulfate binds the EGF ligand heparin-binding egf-like protein (HB-EGF), and loss
of ECM binding of HB-EGF or similar EGF-like ligand amphiregulin may be related to
the chondroma phenotypes observed in Ext1 KO and Mig-6 KO mice [10,41,42]. Calcified
tissue was also identified in the neural canal of the C1 vertebra (atlas), and seemed to be
associated with the transverse ligament based on the anatomical location in microCT scans.
Osteochondromas have been previously described in this same area, further indicating that
there may be human pathologies similar to the phenotypes we observe here [43–45].
Additional research is needed to solidify the role of EGFR signalling, and regulation of this
pathway by Mig-6 and others in the formation of osteochondromas and related diseases.
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Interestingly, the nodule formation described here appears to be independent of TGFα, as
shown by analyses of double KO mice that formed similar nodules as cartilage-specific
Mig-6 KO mice. Although our data show that TGFα is a major EGFR ligand in the joint
[5–7,27,46,47], this could be due to a number of reasons. For example, other EGFR ligands
or different receptor tyrosine kinases could compensate for reduced TGFα signaling
[30,48]. Alternatively, the nodule formation might be independent of an upstream receptor
tyrosine kinase [49]. These possibilities will be investigated in the future. Additionally,
while a male and two female trials were grouped together for analysis, we have consistently
observed similar pathology between sexes in Mig-6 KO experiments ([10] and
unpublished), and do not believe this has introduced any error.
To our knowledge, this is the first study to demonstrate that deletion of Mig-6 in mice can
enhance the anabolic characteristics of articular cartilage that persist through the lifetime
of the animal in multiple joints beyond the knee. We had previously shown that articular
cartilage thickness in cartilage-specific Mig-6 KO animals was increased up to 36 weeks
of age, and others had shown that this phenotype may persist up to 15 months [10,11], but
these studies were restricted to the knee joints that also showed disruptive nodule
formation. At 21 months of age, the articular cartilage of the elbow and ankle showed
robustly increased articular cartilage thickness and staining for GAGs. The articular
cartilage of the knee showed increased thickness in some quadrants of the joint, with the
caveat of increased cartilage degeneration in the form of reduced GAG staining. It is
important to note that despite GAG loss, the structure of the cartilage seemed to be largely
spared in the KO animals examined. Early OA is often preceded by a loss of GAG content
that is followed by collagen II loss and matrix destruction [2], therefore future studies may
need to prolong the time point examined to fully evaluate OA development in these
animals. That being said, mice often show mild-moderate OA by this time in excess of
what we have observed in this study [28]. While we observed minimal effects to the gait
of our Mig-6 KO mice, it may be safe to speculate that normal physiological loading and
articulation in the immobilized knee joints of Mig-6 KO is highly disrupted by nodule
formation. Indeed, destabilization of joint loading and alignment forms the basis of many
of the rodent models we currently employ to study OA development [28]. Therefore, it is
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remarkable to us that more extensive disruption of the articular cartilage was not observed
in these animals.
We do not yet fully understand why our animals do not show more detectable changes to
gait using the CatWalk system. Nodule formation in Mig-6 KO mice causes severe
dysfunction in the articulation of the knee joint, and prevents normal extension [10,11].
However, due to some heterogeneity in the degree and location of nodule formation in the
knees of Mig-6 KO mice [10], the signal may be variable enough to have been lost in the
experimental noise. Furthermore, affected animals may adapt with altered hip and ankle
use to mask the effects of knee dysfunction. Future studies may need additional imaging
techniques to examine joint function in Mig-6 KO animals in real time [50].
In this study we also postnatally deleted Mig-6 in 3 week old mice by tamoxifen induction
of Col2a1-CreER and examined the animals at 12 weeks of age. Tamoxifen induced
CreER(+) animals did not appear to develop any evidence of chondro-osseous nodules,
however these formations may have been too small to detect using the techniques we
employed at that time point. Despite previous results indicating that enhanced cartilage
thickness is present by 12 weeks of age in cartilage specific Mig-6 KO mice [10], and
perhaps at 4 weeks of age, we observed very minor effects on cartilage anabolism in this
study. In fact, we have also shown that nodule development may initiate as early as 6 weeks
of age in the knee [10]. This may indicate that Mig-6 is more important during the
development of the joint, perhaps by enhancing growth of the cartilage structure during
embryonic

or

neo-natal

growth,

or

through

the

modulation

of

resident

chondrocyte/osteoblast precursor cells [13]. However, in depth examination of
developmental time points has not yet been conducted. Future studies may need to examine
additional time points later in the life mice with post-natal deletion of Mig-6, and
embryonic/neo-natal time points of constitutive cartilage specific Mig-6 KO mice.
There are limitations to the methodology used in this study. Early evidence using the
ROSA26mTmG based reporter [19] indicates that only a subpopulation of articular
chondrocytes may be undergoing CreER-mediated recombination. Data produced in our
lab indicate that heterozygous deletion of Mig-6 is insufficient to generate the articular
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cartilage, or ectopic nodule phenotype observed in homozygous Mig-6 KO mice ([10,11]
and unpublished). Compensation for a single Mig-6 copy by similar negative regulators of
EGFR signalling, or partial compensation by other means may overcome the mechanisms
driving the pathology observed with homozygous deletion [10,51,52]. This may be further
complicated by the fact that relative to developing mice, mature animals more infrequently
express the Col2a1 gene which drives CreER expression in our model [21,53]. While at
the age of 3 weeks our animals should have been actively producing some collagen II, it is
possible that recombination efficiency would be better using an alternative CreER driver
line [54]. This is of critical importance considering that our Col2a1-Cre (non-inducible)
Mig-6 KO mice show recombination in cartilaginous tissues including the meniscus and
ligaments [10,55], however we were not able to show recombination in tissues other than
the articular cartilage in our post-natally induced Mig-6 KO mice. Whole body Mig-6 KO
animals [12,16,17] consistently demonstrate more severe chondro-osseous nodule
development than chondrocyte specific models [10,11] potentially due to the involvement
of additional joint tissue involved.
In conclusion, our data suggest that EGFR signalling and modulation by Mig-6 in synovial
joint tissues is highly complex, and effects seem to be both time- and cell-specific.
However, induction of thicker articular cartilage in response to loss of Mig-6 may be
promising for future treatment of OA and other joint degenerative diseases. Further
research is required to evaluate these pathways in joint health and disease.

3.6

Acknowledgements

M.A.P. was supported by a Canadian Institute of Health Research (CIHR) doctoral
scholarship and in part by the Joint Motion Program a CIHR Training Program in
Musculoskeletal Health Research and Leadership. F.B holds the Canada Research Chair in
Musculoskeletal Research. This work was supported by CIHR Operating Grant MOP
86574 to F.B.

141

3.7

Supplementary Figures

Supplementary Figure 3.1 Weights of 21 month old Mig-6 KO and 12 week old
postnatally induced Mig-6 KO are comparable to controls. (A) Weights of 21 month
old female cartilage-specific Mig-6 KO mice and controls taken immediately prior to
sacrifice. Mig-6 KO mice trend towards an increased weight, however the difference is
only 2.500 ± 1.026 g and not significant. (B) Weights taken immediately before sacrifice
of CreER(-) and CreER(+) injected with tamoxifen or vehicle (corn oil) at 3 weeks of age,
and followed until 12 weeks. (A-B) Individual data points presented with mean ± SEM. N
≥ 4. Data analyzed with t-test, or one-way ANOVA with Bonferroni’s multiple
comparisions test.
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Supplementary Figure 3.1 Weights of 21 month old Mig-6 KO and 12 week old
postnatally induced Mig-6 KO are comparable to controls.
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Supplementary Figure 3.2 Ectopic nodules are evident on gross examination of 21
month old Mig-6 KO, but not postnatally induced Mig-6 KO mice. (A) Representative
images of gross examination of the skinned legs of 21 month old Mig-6 KO mice show
ectopic tissue (red asterisk) distending out from the patellar ligament (black asterisk) of
the knee joint. F = femur. T = tibia. (B) Representative images of gross examination of the
knees of 12 week old postnatally induced Mig-6 KO mice show no abnormalities. (A-B)
Scale bars = 200 µm. N ≥ 3.
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Supplementary Figure 3.2 Ectopic nodules are evident on gross examination of 21 month
old Mig-6 KO, but not postnatally induced Mig-6 KO mice.
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Supplementary Figure 3.3 Increased articular cartilage thickness in the ankle, and
absence of ectopic tissue in the ankle and knee of 4 week old Mig-6 KO mice. (A)
Representative images of toluidine blue stained sagittal knee sections of 4 week old control
(left) and Mig-6 KO (right) mice. T = tibia, F = femur. Scale bar = 200 µm. N = 6. (B)
Representative images of toluidine blue stained sagittal ankle sections of 4 week old control
(left) and Mig-6 KO (right) mice. T = tibia, Ta = talus, N = navicular, C = calcaneus. Scale
bar = 200 µm. N = 3. (C) Articular cartilage thickness in the ankle is increased in the talusnavicular joint of 4 week old Mig-6 KO mice. Individual data points are presented with
mean ± SEM. p < 0.05, p < 0.005. N = 3.
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Supplementary Figure 3.3 Increased articular cartilage thickness in the ankle, and
absence of ectopic tissue in the ankle and knee of 4 week old Mig-6 KO mice
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Supplementary Figure 3.4. Chondro-osseous nodules of 5 month old Mig-6 KO mice
are composed of cells that expressed Cre. (A) The ROSA26mTmG reporter was utilized
with Mig-6fl/flCol2a1-Cre mice to visualize cells that have expressed Cre at some point and
activated GFP expression (deactivating RFP expression). Representative image of the
disarticulated knee joint (femur removed) of a 5 month old Mig-6fl/flCol2a1Cre+/ROSA26mTmG mouse shows GFP fluorescence in the nodule (black asterisk) that forms in
the anterior joint space. Cartilage in the patella, tibia, fibula and cruciate ligaments is also
positive for GFP. T = tibia, P = patella. Scale bar = 1 mm. N = 1. (B) Representative
fluorescence images of whole animal cryosectioning shows GFP signal in the knee
cartilage of 5 month old Mig-6 WT and Mig-6 KO mice positive for both Cre and the
mTmG reporter. GFP is also visible in the ectopic tissue (black asterisks) that forms in
the knee joint of Mig-6 KO. F = femur, T = tibia, P = patella. N = 1. Scale bar = 1 mm. (C)
Fluorescence imaging of sagittal knee sections of a Mig-6 KO mouse positive for both Cre
and the mTmG reporter show RFP negative/GFP positive cells in the ectopic nodule (Nod,
dashed white outline) in the anterior knee joint. F = femur, T = tibia, M = meniscus. Scale
bar = 100 µm. N = 1.
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Supplementary Figure 3.4. Chondro-osseous nodules of 5 month old Mig-6 KO mice are
composed of cells that expressed Cre
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Supplementary Figure 3.5 Gait in 21 month old Mig-6 KO mice. The gait of age
matched mice was examined using a Noldus CatWalk apparatus and software (v7.1) for
changes possibly indicative of joint malfunction and/or pain-like behaviours. (A) The duty
cycle (% of time spent in the stand phase of the walk cycle) of the rear limbs trended
towards a decrease in Mig-6 KO mice but was not statistically significant (p=0.073) (B)
Stride length of the rear limbs of Mig-6 KO mice was similar to control mice. (A-B)
Individual data points presented with mean ± SEM. N = 4 age matched. Data analyzed by
t-test.
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Supplementary Figure 3.5 Gait in 21 month old Mig-6 KO mice.
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Supplementary Figure 3.6 Evidence of Cre mediated recombination in 12 week old
tamoxifen induced Mig-6 Col2-CreER mice. (A) Primers flanking the ‘floxed’ region and
one within the Mig-6 allele were used to assess Mig-6 recombination and resultant excision.
Only the ear and xyphoid tissues of the tamoxifen injected CreER(+) mice were strongly
positive for the product of recombination (top band). (B) An additional trial was bred with
ROSAmTmG reporter mice to show localization of Cre recombination. Expression of GFP
follows recombination that was probed for using immunostaining of tamoxifen or vehicle
injected CreER(+) knee joints. GFP positive cells (brown staining) are present in the tibia
tissue of tamoxifen injected CreER(+) mice (two locations shown #1, and #2, right panels).
Vehicle injected controls and no primary exposed control tissue did not show evidence of
GFP staining. Methyl green was used as a counter-stain. Scale bar = 100 µm.
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Supplementary Figure 3.6 Evidence of Cre mediated recombination in 12 week old
tamoxifen induced Mig-6 Col2-CreER mice
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Chapter 4

4

Deletion Of Dual Specificity Phosphatase 1 Does Not
Predispose Mice To Increased Spontaneous Osteoarthritis

These data have been submitted to PLOS ONE 2015-07-30, and are awaiting review:
Pest MA, Pest CA, Bellini MR, Feng Q, Beier F. Deletion of Dual Specificity Phosphatase
1 Does Not Predispose Mice to Increased Spontaneous Osteoarthritis. PLOS ONE,
Submitted 2015-07-30

4.1

Abstract

Background: Osteoarthritis (OA) is a degenerative joint disease with poorly understood
etiology and pathobiology. Mitogen activated protein kinases (MAPKs) including ERK
and p38 play important roles in the mediation of downstream pathways involved in
cartilage

degenerative

processes.

Dual

specificity

phosphatase

1

(DUSP-1)

dephosphorylates the threonine/serine and tyrosine sites on ERK and p38, causing
deactivation of downstream signalling. In this study we examined the role of DUSP-1 in
spontaneous OA development at 21 months of age using a genetically modified mouse
model deficient in Dusp1 (DUSP-1 knockout mouse).

Results: Utilizing histochemical stains of paraffin embedded knee joint sections in Dusp1
knockout and wild type female and male mice, we showed similar structural progression
of cartilage degeneration associated with OA at 21 months of age. A semi-quantitative
cartilage degeneration scoring system also demonstrated similar scores in the various
aspects of the knee joint articular cartilage in Dusp1 knockout and control mice.
Examination of overall articular cartilage thickness in the knee joint further showed similar
results between Dusp1 knockout and wild type mice. Immunostaining for cartilage
neoepitopes DIPEN, TEGE and C1,2C was similar in the cartilage lesion sites and
chondrocyte pericellular matrix of both experimental groups. Likewise, immunostaining
for phosphoERK and MMP-13 showed similar intensity and localization between groups.
SOX9 immunostaining demonstrated a trend towards a decreased number of positive cells
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in Dusp1 knockout mice, with correspondingly decreased staining intensity. Analysis of
animal walking patterns (gait) did not show a discernable difference between groups.

Conclusion: Loss of DUSP-1 does not cause changes in cartilage degeneration and gait
in a mouse model of spontaneous OA at 21 months of age. Subtle changes were observed
in SOX9 immunostaining that may prove promising for future studies examining the role
of DUSPs in cartilage and OA, as well as models of post-traumatic OA.

4.2

Introduction

Osteoarthritis (OA) is a degenerative joint disease that is estimated to afflict at least 10%
of the US population over the age of 25 [1]. Symptoms of OA include joint pain and
stiffness that can become severe enough to limit activity and ability to work. This results
in a substantial loss for both patient quality of life and the economy through missed work
hours and direct healthcare costs [2]. Currently, pharmacological interventions only
mitigate the symptoms of the disease and do not slow, stop or reverse the underlying joint
damage associated with OA, and so further research is needed [2]. While the etiology and
pathophysiology of OA is poorly understood, research has shown that contrary to previous
beliefs that OA was primarily a disease of ‘wear and tear’, there is a complex set of cellular
changes linked to genetic factors and altered biomechanics that occurs in the joint tissues
and influences disease initiation and progression [3].
At the tissue level, chondrocytes are the only active cellular component of the cartilage that
caps the bone in articular joints such as the knee, elbow and ankle. These cells maintain
tissue homeostasis by balancing anabolic buildup and catabolic turnover of surrounding
extracellular matrix (ECM) proteins [2]. The ECM forms the vast majority of cartilage
tissue and consists of a complex network of mostly collagen II and sulfated
glycosaminoglycan (GAG) containing proteoglycans like aggrecan [2]. Matrix production
is largely controlled by the transcription factor SRY (sex determining region Y)-box 9
(SOX9), which also acts as the master regulator of the chondrocyte phenotype [2,4].
Conversely, matrix is catabolized by a number of proteinases produced by chondrocytes
including matrix metalloproteinase (MMP) -3 and MMP-13, as well as various
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aggrecanases [2]. An imbalance in ECM turnover and tissue homeostasis is thought to be
one of the primary underlying reasons for cartilage degeneration in OA. This imbalance is
largely driven by certain growth factors and inflammatory cytokine signalling [2].
Various growth factors have been implicated in OA, including transforming growth factor
beta (TGFβ), fibroblast growth factors (FGF), and transforming growth factor alpha
(TGFα) [5–7]. Previous studies in our lab have shown TGFα mediated activation of
epidermal growth factor receptor (EGFR) induces cartilage degeneration in vitro, and
inhibition of EGFR in vivo partially protects against surgically induced osteoarthritis in
rats [8,9]. A portion of the cellular response to TGFα and other EGFR ligands is mediated
by activation of downstream mitogen activated protein kinases (MAPKs) such as
extracellular signal-regulated kinase 1 and 2 (ERK1/2) and p38 MAPK [8,10–12]. ERK
activation has been shown to induce downstream targets involved in OA including MMPs,
and blockade of MAPK kinase (MEK)/ERK signalling attenuated cartilage degeneration
using in vitro cartilage explant models, and in vivo rabbit models of OA [8,12,13].
Inhibition of p38 has also been shown to partially attenuate production of catabolic MMPs,
and reduce cartilage degeneration and pain-like behaviours in a rat monoiodoacetate (MIA)
induced OA model [14,15]. Furthermore, p38 mediates part of the activity of various
inflammatory cytokines including IL-1β and TNFα, which are important in both
inflammatory arthritis and osteoarthritis [2,16].
Dual-specificity phosphatase 1 (DUSP-1), also known as MAPK phosphatase-1 (MKP-1),
and other DUSP proteins are negative regulators of MAPK signaling [17]. With the ability
to dephosphorylate phosphoserine/phosphothreonine and phosphotyrosine sites, DUSP-1
can deactivate phosphorylated ERK and p38 [17,18]. DUSP-1 has been shown to attenuate
MAPK signaling, effectively reducing osteolysis and cartilage degeneration in studies
utilizing mouse models of lipopolysaccharide (LPS) induced inflammatory bone loss and
collagen induced arthritis (CIA) [16,19,20]. Inhibition of DUSP-1 also increased
chondrocyte apoptosis, which was exacerbated by the cytokine TNFα in cell culture [21].
Our own studies have shown induction of Dusp1 expression in chondrocytes by
pharmacological inhibition of phosphatidylinositol-3-kinase (PI3K) signaling [22].
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However, the role of DUSP-1 in OA has not been closely examined using in vivo animal
models.
In this study, we investigated the role of DUSP-1 in spontaneously occurring OA by aging
mice genetically deficient in Dusp1. We demonstrate that both female and male mutant
animals show similar disease progression to controls at 21 months of age.

4.3
4.3.1

Methods
Animals

All animals were bred in-house, raised, and sacrificed in accordance to the ethical
guidelines of the Canadian Council on Animal Care (CCAC). Animal use protocols were
approved by the Council on Animal Care at Western University – Canada (Animal Use
Permit: 2007-045). Mice were housed on a 12 hour light/dark cycle in standard shoebox
caging with free access to mouse chow and water, but without access to running wheels or
other exercise based enrichments. Mice with a whole body deletion for Dusp1 were
obtained from QF on a mixed C57Bl/6 and 129S2 background [23,24]. Trials were setup
in cages containing at least 1 pair of littermate matched wild type and knockout animals,
with an average of 3-4 mice per cage for the duration of the experiment. All animals were
weighed prior to euthanization by asphyxiation with CO2. Wild type (Dusp1+/+, WT),
heterozygous (Dusp+/-, Het), and Dusp1 knockout (Dusp1-/-, KO) mice were genotyped
using standard PCR techniques on ear tissue biopsies using the following primers: Dusp1
For1 - 5-CCA GGT ACT GTG TCG GTG GTG C-3, Dusp1 For2 - 5-TGC CTG CTC TTT
ACT GAA GGC TC-3, Dusp1 Rev1 - 5-CCT GGC ACA ATC CTC CTA GAC-3 [25].

4.3.2

Histology

Limbs were collected and fixed in 4% paraformaldehyde for 24 hours. The intact joints
were then decalcified in 5% ethylenediaminetetraacetic acid (EDTA) in phosphate buffered
saline (PBS, pH 7.0) for 10 to 12 days at room temperature. Knee joints were processed
and embedded in paraffin to obtain sections 5 µm thick in the frontal orientation. Staining
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with toluidine blue for loss of glycosaminoglycans (GAGs) and cartilage structural changes
was conducted as previously described [26].

4.3.3

Articular Cartilage Evaluation

To evaluate OA related joint degeneration and articular cartilage thickness, 5 evenly spaced
sections spanning a region approximately 500 µm were examined. OA related damage was
assessed using the OARSI approved histological scoring system for mice [27], with all four
quadrants of the joint (medial/lateral tibia and femur) scored by at least 2 blinded observers.
As previously described, the average articular cartilage thickness was measured from the
subchondral bone to the surface of the intact articular cartilage at three evenly spaced points
along the width of each knee joint quadrant (Fig. 4.2C for illustration) using frontally
oriented sections [26].

4.3.4

Immunohistochemistry

Primary antibodies for cartilage and bone matrix breakdown products were received as a
gift from John Mort and included anti-TEGE (aggrecanase mediated aggrecan cleavage
neoepitope), anti-DIPEN (matrix metalloproteinase mediated aggrecan cleavage
neoepitope) and anti-C1,2C (a collagen I and II cleavage neoepitope) and were utilized as
previously described [28–31]. Additional antibodies were obtained from their various
manufacturers: MMP-13 (Proteintech), SOX9 (R&D Systems), phosphoERK1/2 (Cell
Signalling). Sections were incubated for 15 minutes in 3% H2O2 in methanol to eliminate
endogenous peroxidase activity, followed by blocking in 5% goat or donkey serum in PBS,
and overnight incubation with primary antibody at 4ºC. Sections were incubated with the
appropriate secondary antibody (goat anti-rabbit, or donkey anti-goat, Santa Cruz)
conjugated to horseradish peroxidase (HRP) and developed using DAB+ chromogen (Dako
Canada). Both antibody isotype and ‘no primary antibody’ controls were also performed
(data not shown). Sections were counterstained with methyl green, dehydrated in solutions
of increasing ethanol concentration ending in xylene, and cover slipped.
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4.3.5

CatWalk Gait Analysis

Changes in gait and weight bearing were assessed using the Noldus CatWalk system [32–
34]. Animals were transferred to a behavioral facility 2 days prior to assessment. In brief,
animals were allowed to walk freely through a semi-enclosed tunnel along an internally
illuminated glass plate. In a dark room the scattering of the light caused by interaction with
the animal’s paws is detected by a camera, and subsequently interpreted by the
accompanying software (Noldus CatWalk v7.1) as various gait parameters. Stride length
is calculated as the average distance between paw strikes for each limb. Duty cycle is an
expression of the percentage of time the paw remains in contact with the glass plate, relative
to the total gate cycle as shown in this equation: Duty Cycle = [Stand Time/(Stand Time
+ Swing Time)] x 100%. Print area and paw intensity are related to the amount of weight
the animal bears on an individual paw, with the maximal contact area and maximal
intensity of light measured respectively.

4.3.6

Statistical Analysis

All data were analyzed for statistical significance using GraphPad Prism (v6.0) and the
appropriate statistical techniques (two-way ANOVA or t-tests as indicated). Outliers were
assessed using the Grubbs’ outlier test.

4.4
4.4.1

Results
DUSP-1 KO animals show good general health up to 21 months of
age

At 21 months of age, most Dusp1 KO, HET, and WT control mice appeared to be generally
healthy. A small number of animals demonstrated repeated skin ulcerations and were
withdrawn from the trial, or died from unknown causes prior to 21 months of age (Supp.
Table 1). Animal weights were taken at 21 months immediately prior to sacrifice to
evaluate possible metabolic changes due to loss of Dusp1. Female animals showed no
statistically significant difference in weight, however male WT mice were on average 7.8
g heavier (p=0.038) than their KO littermates (Supp. Fig. 1).
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4.4.2

DUSP-1 KO animals are not protected from the histological
changes associated with spontaneous OA

At 21 months of age, Dusp1 KO and WT littermate control mice were sacrificed and knee
joints harvested for histological evaluation of joint health. Slides of frontally embedded,
toluidine blue stained mouse knees were evaluated for OA related histological changes by
at least 2 blinded observers, using the OARSI recommended cartilage degeneration scoring
system [27]. In both female (n=8) and male (n=5) trials of Dusp1 KO and WT control mice,
no statistically significant differences in joint degeneration were observed in the
individually examined joint quadrants, nor the summed total joint score (Fig. 4.1A-D).
Similarly, when we compared the scores of male to female cohorts, no significantly
different findings were observed between any pairing of groups. In both male and female
cohorts, a single animal showed larger than average cartilage degeneration, particularly in
the medial tibial plateau (MTP). When these points were assessed as outliers using the
Grubbs’ test and excluded, the results noted did not change conclusions on statistical
significance, so they remained included for the reported data (Fig. 4.1CD).
To directly evaluate any differences in the articular cartilage thickness in the knee joints of
Dusp1 KO and control WT mice, the distance from the subchondral bone to the surface of
the intact articular cartilage was measured. No statistically significant differences were
observed when comparing male KO to WT or female KO to WT animals (Fig. 4.2AB).

4.4.3

DUSP-1 KO mice show similar levels of cartilage breakdown
products

Following the catabolic activities of various metalloproteinases (MMPs, aggrecanases,
etc.) on ECM proteins, neoepitopes are formed at either side of the cleavage site, and can
be detected using specialized antibodies. We utilized antibodies for neoepitopes formed
through aggrecan and collagen II cleavage to evaluate any differences in the pattern of
cartilage degeneration in our Dusp1 KO mice. The DIPEN neoepitope is formed when the
interglobular domain (IGD) of the aggrecan core protein is cleaved by MMPs, and
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Figure 4.1 Dusp1 KO mice show similar cartilage damage as controls at 21 months of
age Dusp1 KO and WT control animals were aged to 21 months and right knees were
evaluated for cartilage damage following OARSI recommended guidelines. (A-B)
Representative toluidine blue stained frontal knee section images of the lateral (Lat.) and
medial (Med.) femur (F) and tibia (T) of (A) female (n=8) and (B) male (n=5) mice, least
damaged (left) and most damage (right), wild type controls (WT, top) and Dusp1 knockout
(KO, bottom). Lesion (red arrowheads) location patterns and size were similar between
WT and KO groups. Scale bars = 100 µm. (C-D) Total OARSI cartilage degeneration
scores across the lateral tibial plateau (LTP), lateral femoral condyle (LFC), medial tibial
plateau (MTP), medial femoral condyle (MFC), and cumulative joint score (Total Joint) of
(C) female (n=8) and (D) male (n=5) WT and KO mice. OARSI scores did not show
statistically significant differences between WT and KO groups when analyzed by twoway ANOVA with Bonferroni’s multiple comparisons test. Error bars are shown as SEM.
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Figure 4.1 Dusp1 KO mice show similar cartilage damage as controls at 21 months of age
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Figure 4.2. Dusp1 KO mice show similar articular cartilage thickness when compared
to controls. Measurements from the subchondral bone to the intact articular cartilage
surface were made at 3 points across the lateral tibial plateau (LTP), lateral femoral condyle
(LFC), medial tibial plateau (MTP) or medial femoral condyle (MFC) and averaged. (A)
Female (n=8) and (B) male (n=5) Dusp1 KO mice do not show statistically significantly
different articular cartilage thickness when compared to WT controls. Analyzed by twoway ANOVA with Bonferroni’s multiple comparisons test. Error bars are shown as SEM.
(C) Example diagram demonstrating approximate sites of articular cartilage measurements
indicated by dashed red lines. F = femur, T = tibia, Lat. = lateral, Med. = medial.
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Figure 4.2 Dusp1 KO mice show similar articular cartilage thickness when compared to
controls
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represents the new N-terminal of the cleaved aggrecan protein [29]. Likewise, the TEGE
neoepitope represents the new N-terminal in the IGD of aggrecanase cleaved aggrecan
[30]. Collagen breakdown product neoepitopes can also be similarly identified. The
products of MMP mediated cleavage of both collagen I and II form ¾ and ¼ length
fragments. The C-terminal of the ¾ fragment is known as the neoepitope C1,2C [31].
No large qualitative differences could be identified when examining immunostained knee
sections from either female (n=6, Fig. 4.3A) or male (n=5, Fig. 4.3B) Dusp1 KO and WT
control mice. Staining for DIPEN was most pronounced in the matrix of the cartilage
lesion, with additional chondrocyte pericellular matrix staining observed in many animals
(Fig. 4.3). Weak matrix staining for the TEGE neoepitope was observed in the ECM of
cartilage lesions, however little chondrocyte pericellular matrix staining was evident in the
MTP (Fig. 4.3). Conversely, increased staining was evident in the pericellular region of
chondrocytes in the lateral tibial plateau (LTP) and lateral femoral condyle (LFC) of both
male and female animals (data not shown). C1,2C immunostaining was found present only
in ECM of the cartilage lesion sites (Fig. 4.3).
Interestingly, the growth plates (tibia and femur) of both female and male animals showed
intense DIPEN immunostaining throughout the cartilage matrix (Supp. Fig. 4.2A), but no
differences between genotypes were observed. Immunostaining for MMP-13 in the same
regions did not appear to be particularly strong, and no differences were noted between
WT and KO for either female or male groups (Supp. Fig. 4.2B).

4.4.4

Loss of DUSP-1 causes an imbalance in anabolic but not catabolic
chondrocyte activity

The DUSP-1 target ERK mediates the effects of many cell surface receptors including
EGFR. Immunostaining for the phosphorylated activated form of ERK (phERK) showed
similar staining patterns and intensity in the lateral knee compartment of female Dusp1 KO
and WT animals (Fig 4.4A) and males (data not shown). However, little to no cellular
staining was observed in the medial compartment of the knee for any group (data not
shown).
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Figure 4.3. Cartilage matrix neoepitope immunostaining shows similar intensity and
localization in Dusp1 KO and WT control mice. (A) Female (n=6) and (B) male (n=5)
representative medial femur (F) and tibia (T) joint sections were immunostained for:
DIPEN (Top, MMP cleaved aggrecan neoepitope), TEGE (Middle, aggrecanase cleaved
aggrecan neoepitope), and C1,2C (Bottom, MMP cleaved collagen II/I). Regions of
pericellular and extracellular matrix (ECM) staining are indicated by the black arrowheads.
Scale bars = 100 µm.
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Figure 4.3 Cartilage matrix neoepitope immunostaining shows similar intensity and
localization in Dusp1 KO and WT control mice
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Matrix metalloproteinase 13 (MMP-13) cleaves both collagen II (C1,2C neoepitope) as
well as aggrecan ECM molecules (DIPEN neoepitope), and has been implicated as one of
the key mediators of cartilage destruction in OA [35]. Immunostaining for MMP-13 in
knee joint articular cartilage was localized largely to the chondrocyte pericellular ECM and
surrounding cartilage matrix immediately adjacent to lesion sites in female (Fig. 4.4B) and
male (data not shown) mice. Little difference was noted for MMP-13 staining between WT
and KO animals, which is compatible with previous observations for DIPEN and C1,2C
neoepitope staining as noted above.
SOX9 is the master regulator of the chondrocyte cellular phenotype, and is important in
both establishing a chondrocyte lineage during development as well as maintaining that
phenotype in adult tissues [4]. In the lateral compartment of the knee joints of female Dusp1
KO mice the intensity of SOX9 immunostaining was decreased in the articular cartilage
chondrocytes and meniscus when compared to WT controls (Fig. 4.4C). Similar results
were observed in male animals (data not shown), however, little cellular staining was
observed in the medial compartment of either sex (data not shown). The number of SOX9
positive cells in female animals also trended towards a decrease in KO vs WT (p=0.095),
but was not found to be statistically significant (Fig. 4.4D).

4.4.5

The gait of DUSP-1 KO mice is comparable to WT mice

To evaluate changes in the gait patterns of our aged Dusp1 KO mice vs WT controls, we
utilized the Noldus CatWalk apparatus, which measures parameters of rodent walking
patterns. We examined 4 of these parameters, including stride length, duty cycle, print area
and paw intensity. No statistically significant differences were found comparing the stride
length of the hind limbs of WT vs KO female (Fig. 4.5A) and male (Fig. 4.5B) animals.
Similarly, duty cycle (% time in stand phase of walk cycle) was not found to be statistically
significantly different between WT vs KO female (Fig. 4.5C) and male (Fig. 4.5D)
animals. For both print area and paw intensity, no statistically significant differences were
observed between female or male WT vs KO animals when normalized to animal weights
(data not shown).
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Figure 4.4. Decrease in cartilage anabolism marker SOX9 in Dusp1 KO mice. (A)
Representative phosphoERK (phERK) immunostained female (n=6) lateral femur (F) and
tibia (T) joint images show similar cellular staining (arrowheads) in Dusp1 KO and WT
control mice. (B) Representative MMP-13 immunostained female (n=6) medial femur (F)
and tibia (T) joint images show similar pericellular and matrix staining (arrowheads) in
Dusp1 KO and WT control mice. (C) Representative SOX9 immunostained female (n=6)
medial femur (F) and tibia (T) joint images show decreased staining intensity and positive
cells (arrowheads) in Dusp1 KO mice when compared to WT controls. All scale bars = 100
µm. (D) The number of SOX9 positive cells in female Dusp1 KO mice was decreased but
not statistically significantly different (p=0.095) from WT controls. Analyzed by unpaired
t-test. Error bars are shown as SEM.
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Figure 4.4 Decrease in cartilage anabolism marker SOX9 in Dusp1 KO mice
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Fig. 4.5. Gait patterns are not different in Dusp1 KO mice at 21 months of age. Gait
patterns of Dusp1 KO and WT control mice were measured using the Noldus CatWalk
apparatus prior to sacrifice at 21 months of age. (A) Female (n=5) and (B) male (n=5) stride
length (distance between individual hind paw prints during gait) were not statistically
different between WT and KO mice. (C) Female (n=5) and (D) male (n=5) duty cycle (%
of time in stand phase of walk cycle) was also not statistically different between WT and
KO mice. Data analyzed by unpaired t-tests. Error bars are shown as SEM.
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Figure 4.5 Gait patterns are not different in Dusp1 KO mice at 21 months of age
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4.5

Discussion

In this study on the effects of loss of Dusp1 on spontaneous OA in mice, we demonstrated
little difference between both female and male Dusp1 KO and WT control mice in terms
of OA related cartilage damage and gait changes.
Spontaneous OA can be particularly difficult to study as it may take months to years to
develop even in rodent models that develop spontaneous OA-like cartilage damage within
2 years of life [36]. This is in contrast to induced OA models using surgical or chemical
methods that model more rapidly developing post-traumatic OA in months or less [36].
Our lab has previously examined mice on the C57Bl/6 background at 21 months of age and
has found that they develop mild to moderate OA by this time point (unpublished data).
Other studies have shown similar results [37]. While our lab has also shown that F1
C57Bl/6 x 129/SV crossed mice develop mild to moderate OA by 2 years of age [38],
future studies should consider using sufficiently backcrossed congenic C57Bl/6 or 129
strain mice to reduce possible confounding genetic variability. However, the severity of
OA observed on our mixed background was similar to that seen in our previous work in
C57Bl/6 mice.
Previous studies indicate the importance of both ERK and p38 in the progression and
initiation of arthritis [8,15] as well as the role of DUSP-1 in the negative regulation of these
MAPKs [17,24,39]. Despite this we were unable to show any difference in cartilage
degeneration when Dusp1 was genetically removed from our mouse model. This may be
in part due to the incredibly complex and dynamic regulation of these particular factors.
Both ERK and p38 are regulated at multiple levels (expression, post-translational
modification, etc.), with various negative and positive feedback loops, and many different
signalling pathways converging on these molecules [10,40]. Therefore, while we may have
removed DUSP-1 from our KO mice, the net effect may have been largely mitigated by
increased negative feedback or various other factors. Furthermore, compensation by other
DUSP protein family members (Reviewed in [17]) may have also counteracted for loss of
DUSP-1 in our model, which is consistent with the minimal changes in cartilage phERK
immunostaining observed in KO animals. Future studies may need to focus further
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upstream at the receptor level, or downstream at specific transcription factors to gain more
insight into the pathobiology of OA and related diseases.
Interestingly, in this study we demonstrated a large increase in the immunostaining for
MMP cleaved aggrecan neoepitope DIPEN in the growth plate of our aged animals. To our
knowledge, this has not been previously described. Oddly, MMP-13, which is considered
one of the primary proteinases in cartilage ECM breakdown [2,35], did not show
particularly robust staining in the same regions. This may be due to the time point at which
we examined our animals, particularly if MMP-13 is transiently expressed and the cleaved
aggrecan fragments are unable to diffuse out of the growth plate due to otherwise intact
ECM protein network structure or restriction by surrounding bone.
In this study we demonstrated a small decrease in SOX9 staining with a trend towards
fewer stained cells in Dusp1 KO animals, although this was not shown to be statistically
significantly different. Previous studies have shown a negative regulatory role for ERK in
SOX9 driven chondrogenesis [41,42]. Furthermore, studies in our lab have shown that
MEK/ERK inhibition can reverse TGFα/EGFR mediated repression of Sox9 expression
[8]. However, regulation of SOX9 is complex and poorly understood, and other studies
have shown that ERK increases SOX9 at the mRNA and protein levels [26,43,44],and p38
may stabilize Sox9 mRNA [45]. Since our study did not show a large difference in phERK
immunostaining, temporal factors, and other DUSP proteins or unknown pathways may be
involved in compensating for loss of DUSP-1 in vivo. Further research is required to
elaborate on the role of DUSP-1 and MAPK signalling in the regulation of SOX9.
While the weight of the male control animals was on average higher than the KO group,
we did not observe any differences in OA development that is known to be influenced by
obesity in humans [2]. It is unknown why the female cohort did not demonstrate a similar
difference in weights, but this may be due to differences in hormonal control in males and
females that is influenced by ERK signalling and may have been modulated by whole body
loss of Dusp1 in this study [46].
While evaluating limb pain in rodent models is difficult to assess and widely debated,
analysis of gait changes has begun to gain favour as a measure of behaviours related to
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OA-like pain and joint dysfunction [33,34,47]. To evaluate gait changes possibly due to
OA development in our study, we utilized the Noldus CatWalk gait analysis system. While
we were unable to show any differences between Dusp1 KO and control mice in the gait
variables examined, it is still possible that these animals experienced increased OA related
changes in gait. Due to the limitations of the equipment, and the nature of spontaneous OA
presenting as a bilateral or unilateral disease, any small but present changes in gait pattern
may have been lost in the noise. Interestingly, mice have been shown to mask signs of pain
with male observers (MP performed all CatWalk data acquisition), possibly making it
difficult to assess changes in gait and perhaps OA related pain-like behaviours [48].
Furthermore, it is difficult to determine the cause of gait changes, as muscle weakness due
to aging, physical dysfunction of the joint due to cartilage or bone degeneration, and pain
all may influence animal gait behaviours.
In conclusion, we were unable to demonstrate any definitive evidence that DUSP-1 plays
an important role in spontaneous OA development in mice. However, future research is
needed to evaluate if DUSP-1 may play a role in the more rapid progression of cartilage
degeneration as seen in post-traumatic OA, and if other DUSP proteins can compensate for
the loss of DUSP-1.
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4.7

Supplementary Tables

Supplementary Table 4.1. Dusp1 KO mice are generally healthy at 21 months. Dusp1
WT (Dusp1-/-), Het (Dusp1+/-), KO (Dusp1-/-) animals live and healthy (Live) at the end of
the experiment, or removed from the experiment due to recurrent skin ulcerations/died of
unknown causes (Dead/Rem.).
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%
Female Live Dead/Rem.

Live

WT

9

1

90.0

Het

8

1

88.9

KO

9

2

81.8

%
Male

Live Dead/Rem.

Live

WT

7

1

87.5

Het

5

0

100.0

KO

7

1

87.5

Supplementary Table 4.1. Dusp1 KO mice are generally healthy at 21 months.
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4.8

Supplementary Figures

Supplementary Figure 4.1 Male Dusp1 KO are lighter than WT controls. Animal
weights were taken at 21 months prior to sacrifice. Male (n=5) Dusp1 KO mice were on
average 7.8 grams lighter than WT controls. Female (n=6) Dusp1 KO and WT mice
showed no statistically significant differences in weight. Data analyzed by two-way
ANOVA with Bonferroni’s multiple comparisons test. Error bars are shown as SEM.
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Supplementary Figure 4.1 Male Dusp1 KO are lighter than WT controls.
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Supplementary Figure 2 Intense DIPEN but not MMP-13 immunostaining in the
growth plate of Dusp1 KO and WT mice. Female frontal knee sections were
immunostained for (A) DIPEN (MMP cleaved aggrecan neoepitope) and (B) MMP-13.
DIPEN staining in both WT and KO growth plates is intense despite poor staining for
MMP-13. Scale bar = 100 um. Representative images shown. N=6.
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Supplementary Figure 2 Intense DIPEN but not MMP-13 immunostaining in the growth
plate of Dusp1 KO and WT mice.
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Chapter 5

5

Discussion

5.1

Overview

The overall goal of my thesis was to evaluate the role of epidermal growth factor receptor
(EGFR) signalling in cartilage biology. I was particularly interested in evaluating the
involvement of factors regulating both the EGFR receptor and downstream signalling
pathways involved in osteoarthritis (OA), namely mitogen-inducible gene 6 (Mig-6) and
dual specificity phosphatase 1 (DUSP-1). My lab has been closely studying the role of
EGFR signalling in cartilage biology and pathology, particularly its ligand, transforming
growth factor alpha (TGFα), since microarray studies identified it to be increased in
cartilage isolated from a surgical rat model of OA [1,2]. Additional studies further
demonstrated that TGFα appeared to play a role in the induction of cartilage degeneration
and alteration of the healthy chondrocyte phenotype [3,4]. These studies and additional
literature demonstrating evidence for EGFR signalling involvement in the alteration of
cartilage homeostasis [1–12], encouraged us to explore the various downstream pathways,
and regulatory mechanisms that may be in play. Since Mig-6 had been identified as an
important regulator of EGFR signalling [13,14], and genetic knockout (KO) studies had
shown cartilage degeneration similar to that seen in animal models of OA [9,10], it
appeared to be a good candidate for further study into the role of EGFR signalling in
cartilage homeostasis.
The first study conducted for my thesis involved the cartilage-specific deletion of Mig-6
(please note that the gene encoding for Mig-6 is Errfi1, however I will use Mig-6 notation
for simplicity) in mice, utilizing a Col2a1-Cre mouse [15] to selectively delete Mig-6 from
chondrocytes with a recently generated ‘floxed’ Mig-6fl/fl conditional KO mouse obtained
from our collaborators [10]. Based on previous findings that TGFα induced EGFR
signalling was associated with cartilage degeneration [1–4], and systemic loss of Mig-6 in
mice resulted in joint pathology similar to OA [9,10] I hypothesized that cartilage-specific
deletion of Mig-6 would lead to premature development of OA in these animals due to
overactive EGFR signalling. Interestingly, we found an unexpected mixture of both
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anabolic and catabolic phenotypes present in these Mig-6 knockout (KO) animals. The
articular cartilage in the knee joints of Mig-6 KO mice demonstrated drastically increased
thickness. However, these animals also developed large invasive chondro-osseous nodules
in their knee joints and spine similar to previous whole body Mig-6 KO models [9,10].
Interestingly, little evidence of cartilage degeneration was apparent. The central ligaments
in the knee joints of KO mice also demonstrated cartilage neogenesis, and were associated
with an osteolytic phenotype at the ligament entheses. Tartrate resistant acid phostphatase
(TRAP) staining, indicative of osteoclast activity, was increased in the knee entheses, and
both subchondral and trabecular bone. It appeared that these phenotypes were associated
with increased EGFR activation, and induction of SOX9, for which immunostaining was
increased in both the articular cartilage and the chondro-osseous nodules that developed in
KO mice. Taken together, it appeared that loss of Mig-6 appears to induce an anabolic
phenotype in articular cartilage and produce ectopic chondro-osseous growths, however it
also resulted in activation of catabolic activity through osteoclast activation. Thus, I
concluded that Mig-6 regulates both anabolic activity in articular cartilage and catabolic
activity in surrounding bone.
However, Mig-6 had not been studied in mice past their first year of life when OA generally
begins to develop [16], and post-natal modulation of Mig-6 in mice had not been previously
attempted, which led into my second study. I again utilized our cartilage specific Mig-6
KO mouse model, and housed these animals until 21 months of age. Examination of the
knee, elbow, and ankle joints of Mig-6 KO mice showed increased articular cartilage
thickness was present in all of these joints, and could be maintained until 21 months of age
near the end of their life span. Furthermore, while KO mice did show increased cartilage
matrix loss relative to controls, overall OA-like pathology was surprisingly low. In an
additional experiment, I introduced the Tgfa null mutation previously studied in our lab
[6,17] to the constitutive Mig-6 KO mice. These mice showed similar formation of
chondro-osseous nodules in the knee despite the absence of TGFα. This lead me to
conclude that TGFα is not essential for initiating the formation of nodules in Mig-6 KO
mice, and that compensation by other EGF-family ligands found in the joint [18,19] may
be involved, although other possibilities could explain this phenotype (ex. EGFRindependent effects). I then pursued the post-natal deletion of Mig-6 in mouse cartilage
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using a tamoxifen inducible Col2a1-CreER mouse line [20] with the Mig-6fl/fl mice
described above. Initiation of CreER mediated Mig-6fl/fl recombination in chondrocytes
with tamoxifen at 3 weeks was followed up at 12 weeks of age. Despite previous evidence
that constitutive cartilage specific Mig-6 deletion leads to rapid development of cartilage
nodules [10,9] and enhanced cartilage thickness by 12 weeks of age, I did not observe
similar phenotypes in these CreER-based experiments. I concluded that loss of Mig-6 in
cartilage may not be directly responsible for OA-like degeneration previously observed,
and may in fact promote long term cartilage health. Furthermore, based on the CreER
experiments, I suspect that the phenotype of constitutive Mig-6 KO mice may be at least
partially influenced by developmental factors.
Finally, I turned my attention to DUSP-1, a phosphatase that deactivates mitogen-activated
protein kinase (MAPK) signalling downstream of EGFR activation [21], and had appeared
in our own genome wide studies examining endochondral ossification [22]. Studies in
inflammatory forms of arthritis demonstrated that DUSP-1 had a protective effect in animal
models [23–25], and thus was a good candidate to assess for its potential role in OA and
maintenance of cartilage health. Utilizing a whole body Dusp1 KO mouse line obtained
from our colleague [26,27], I initiated a study on spontaneous age-related OA in these
animals with the hypothesis that loss of DUSP-1 would lead to dysregulation of signalling
downstream of EGFR activation, and would result in exacerbated spontaneous OA.
Examining the knee joints of these mice at 21 months of age, I found similar levels of
cartilage degeneration in both Dusp1 KO mice and controls. The chondrocytes of KO mice
did not appear to show increased levels of phospho-ERK, indicating that loss of DUSP-1
was likely being compensated for by other mechanisms [21]. However, a slight decrease
in SOX9 was evident by immunostaining, indicating that DUSP-1 may play a role in
regulation of chondrogenic behaviour. With these findings, I concluded that loss of DUSP1 alone is insufficient to influence age-related spontaneous OA.
Taken together these studies demonstrate that regulation of EGFR signalling plays a
complex but important role in the maintenance of joint homeostasis (Fig. 5.1). It is clear,
however, that Mig-6 is important for the fine tuning of anabolic activity within articular
cartilage, and the entire joint. Furthermore, SOX9 modulation was present in all three
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Figure 5.1 Regulation of EGFR signalling in joint homeostasis. Epidermal growth
factor receptor (EGFR) signalling influences the homeostasis of multiple tissue types in
the synovial joint. Loss of Mig-6 disrupts regulation of EGFR resulting in increased
downstream signalling. Resultant increases in SOX9 and ERK activity may induce the
formation of abnormal ectopic tissue, and increased anabolic activity within the articular
cartilage. Increased EGFR signalling may also enhance osteoclast activity, leading to bone
remodeling within the joint. DUSP-1 regulates ERK and p38 signalling that may lead to
joint pathology, however this thesis demonstrated that loss of DUSP-1 alone is insufficient
to lead to increased cartilage degeneration. ROCK (rho-kinase) activation may also lead to
increased cartilage degeneration [4], but additional research is needed.
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Figure 5.1 Regulation of EGFR signalling in joint homeostasis
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studies, and supports evidence that EGFR signalling may play an important role in the
complex regulation of this master chondrocyte transcription factor.

5.2
5.2.1

Contributions and Significance of Findings
Contributions to the Field of Skeletal Biology

Chapters 2 and 3 of this thesis focus on the characterization of Mig-6 KO mice, and the
fascinating anabolic and catabolic phenotypes that these animals exhibit. Studies prior to
my work showed that systemic loss of Mig-6 resulted in considerable pathology in the form
of chondro-osseous growths in a variety of joints including the knee, ankle, and
temporomandibular joint (TMJ) [9,10]. Additionally, a study utilizing Prx1-Cre to drive
the deletion of Mig-6 in the entire limb with the same Mig-6fl/fl line [10] used in my
experiments showed similar ectopic growths in the knee joint [28] (this study was
published while my work was underway). However, the tissue of origin of these growths
was uncertain, as Mig-6 was not present in any of the joint tissues of KO animals. Using
chondrocyte-specific deletion of Mig-6, I was one of the first to demonstrate that the
cartilaginous tissue of the joints of these KO animals was contributing to these ectopic
formations. A similar study was conducted by one of our collaborators and published
shortly prior to the publication of our manuscript [29], however, this work was conducted
using a novel Mig-6fl/fl mouse line [29], and deletion in chondrocytes was driven by a
different Col2a1-Cre driver line [30]. Their study showed similar phenotypes in the knee
joint, with extensive nodule formation that progressed at a rate similar to my Mig-6 KO
mice [31]. Both models did not show any formation of nodules within the TMJ that allowed
us to characterize the pathology in the knee joint far longer than previous studies, as our
KO mice survived past 3-6 months [9,10]. However, while their study examined the knee
joints of cartilage specific KO mice at 15 months of age [29], they did not pursue other
joints. Conversely, I have examined the entire calcified skeletons of 36 week old mice via
micro-computed tomography (microCT) and shown that the spines of 36 week old Mig-6
KO mice form calcified nodules, but these mice do not appear to exhibit abnormal
formation of calcified tissues in other joints. Regardless, these two studies complement
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each other well and demonstrate that the findings are not due to artifacts of the genetic
models utilized.
In chapter 3, I extend these studies to additional time points and outcome parameters. I
describe the formation of nodules in the spine, ribs, and knees of 21 month old cartilage
specific Mig-6 KO mice. Similar to data shown in Chapter 2, I closely examined the
calcified skeleton of Mig-6 KO mice and did not note the formation of calcified nodules in
joints other than the knee and spine. Furthermore, histology of the ankle and elbow
confirmed the absence of non-calcified growths in these joints. Additional work is needed
to explain the apparent joint specificity observed, however, I have shown evidence that
these growths are commonly associated with the supportive ligaments and menisci found
in the knee, which establishes a basis for future mechanistic studies.
While the exact mechanism driving the formation of these chondro-osseous nodules in
Mig-6 KO animals is unknown, a common theme appears to be the increased presence of
activated EGFR within the chondrocyte-like cells that make up these growths [28,29,31]
and the articular cartilage [28,29,31,32]. Ligand binding is important for the initial
activation of EGFR in our Mig-6 KO animals, and I suggest that an initial mechanical or
biochemical insult may be required to initiate pathology. I have observed that some Mig-6
KO animals do not always show bilateral development of nodules in the knee joint, while
still exhibiting increased articular cartilage thickness. Impact models of cartilage damage
have shown alterations in Mig-6 expression following mechanical injury [33–35],
demonstrating that Mig-6 and EGFR are likely sensitive to these types of insult, perhaps
due to EGF-family ligand activation as shown with ADAM17 activated amphiregulin and
TGFα shedding [36–38]. Along these lines, I am the first to demonstrate evidence that
TGFα is not required for nodule development in Mig-6 KO Tgfa null mice. However,
further inquiry is required.
Additionally, I demonstrated that strong immunostaining for SOX9 is present in the
chondro-osseous nodules in the knee joints of Mig-6 KO mice, and may be driving growth
of these neoplasms through expression of a proliferating chondrocyte phenotype. SOX9
has been shown to drive the growth of a number of different sarcomas [39], and so the
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model I have established here may prove useful for the future study of benign and
malignant tumours of mesenchymal origin.
Interestingly, I showed that post-natal cartilage-specific deletion of Mig-6 in 3 week old
mice, is insufficient to generate the cartilage growths observed in other constitutive Mig-6
KO models, at least when examined at 12 weeks of age. While additional work is required
to examine this effect in detail, previous studies have identified that the cells in the
expanded superficial and mid zone cartilage layers of Prx1-Cre driven Mig-6 KO mice
express putative markers of resident chondroprogenitors [28,40]. It is possible that these
cells are responsible for driving the anabolic growth of articular cartilage and formation of
chondro-osseous nodules observed in the various Mig-6 KO studies [9,10,28,29,32]. Since
these cells may not be actively transcribing collagen II at the time point chosen, the Col2a1CreER system used in my post-natal experiments may not have adequately targeted these
cells, which may help to explain the lack of obvious phenotype observed in these
experiments. Furthermore, evidence of Cre recombination in the synovium has been shown
in Col2a1-Cre mice despite lack of Cre expression in post-natal tissue, likely due to shared
developmental precursors that express Col2a1 [41]. The nodules that develop in the
synovial tissue in classical Col2a1-Cre Mig-6 KO mice may derive from these cells, and
would not be targeted in my Col2a1-CreER based experiments, further explaining the lack
of phenotype observed.
Finally, the work I present in this thesis is the first to show increased osteoclast activity in
the subchondral bone, nodule bone junction, and the entheses of the knee ligaments as a
result of cartilage-specific deletion of Mig-6. A study utilizing whole body Mig-6 KO in
mice, previously described [9], with additional surgical transection of supportive ligaments
to induce instability in the knee joint, demonstrated similar increases in TRAP staining in
the subchondral bone 2-4 weeks following surgery in KO animals [32]. However, it was
not clear whether this was due largely to loss of Mig-6, or exacerbated by surgical
intervention. Furthermore, this study did not examine in detail osteoclast-driven osteolysis
of the ligament entheses of the joint. TGFα and EGF induced production of RANKL and
subsequent osteoclast recruitment has been shown previously by our lab, and our
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colleagues [6,12]. Thus my studies support the notion that EGFR driven signalling is
important for induction of osteoclast activity in the knee joint.

5.2.2

Contribution to the Field of Osteoarthritis

In these studies I show that loss of Mig-6 in cartilage causes increased thickness of articular
cartilage in the knee, ankle, and elbow that is largely resistant to thinning or degeneration,
even in 21 month-old mice. Similar results have been described in the knee up to 15 months
in a study using a unique Mig-6fl/fl and Col2a1-Cre driver line discussed above [29].
Previous reports using whole body Mig-6 KO mice have shown rapid thinning and
degeneration of cartilage by 4-6 months of age [9,10,28,32], however I would suggest that
these effects may be in large part secondary to joint immobilization, instability, and
articular cartilage impingement caused by the chondro-osseous nodules that develop in
these joints, similar to conditions used in animal models of secondary OA [16]. This view
is supported by my data that shows the joints of Mig-6 KO mice that are unaffected by
nodule formation, the elbow and ankle, exhibit robust articular cartilage thickness with
little evidence of loss of glycosaminoglycan staining. Although there is little published on
the use of EGF-family ligands in joint tissue repair, a study showing enhanced in vitro
expansion human chondrocytes by EGF [42] may indicate a role for Mig-6 and EGFR
signalling in the field of cartilaginous tissue regeneration.
Extensive work in my lab has provided evidence for a role of TGFα in OA, and has shown
that TGFα induces the expression of catabolic MMPs and the repression of ECM protein
production [1–6,11,43]. Furthermore, HB-EGF stimulation of cartilage shows similar
effects [18]. However, the results of my studies have shown quite the opposite phenotype
in the articular cartilage, even though activation of EGFR signalling has been shown in the
Mig-6 KO model. Similarly, a recent study published by our colleagues demonstrated that
pharmacological inhibition and genetic ablation of EGFR in rodent models resulted in
increased articular cartilage destruction, supporting the role of EGFR in the maintenance
of cartilage health during OA [44]. These apparent opposing roles are difficult to reconcile,
however, regulation of EGFR is highly complex, and downstream signalling pathways may
be highly ligand and context specific [45–47]. Mig-6 is important in EGFR desensitization
and receptor internalization, a highly complex process that is important for the complete
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activation of certain EGFR signalling pathways, and may also be important in the function
of EGFR as a putative nuclear receptor [48–50]. Therefore while I have shown increased
EGFR activation with loss of Mig-6, the disruption of normal intracellular trafficking may
have interesting consequences that are not evident when EGFR is activated by increased
environmental ligand alone.
This is the first report on the role of DUSP-1 in long term cartilage health and spontaneous
OA. While we did not show significant differences between KO and control animals in
terms of cartilage degeneration, these data do provide evidence that there may be other
mechanisms present in articular cartilage that compensate for the loss of MAPK regulation
by DUSP-1. In fact, DUSP-1 deactivates both p38 and ERK proteins [21], which may have
opposing effects in cartilage health [4,8,51–55]. Blockade of ERK signalling has been
shown to ameliorate cartilage degeneration both in vitro and in vivo [4,8], while p38
inhibition in vivo exacerbates cartilage degeneration via induction of catabolic enzymes
like MMP-13 [51]. However, there seems to be conflicting evidence available for both of
these MAPK pathways [4,52–55]. Likewise, MAPK pathway mediated regulation of
SOX9, which is important in maintenance of the articular chondrocyte phenotype, is also
highly complex and is currently fraught with apparent contradictions [4,31,56–58].
Considering this, it is possible that in my study the effect of loss of DUSP-1 on both p38
and ERK is partially opposing and results in only a slight net decrease in SOX9 and a
negligible change in MMP-13 immunostaining in KO tissues. Furthermore, while I also
showed an increase in SOX9 immunostaining in the articular cartilage of Mig-6 KO
animals, the precise mechanism is unknown, for similar reasons as presented above.
Therefore, additional research is required to elucidate the role of EGFR and MAPK
signalling in the regulation of SOX9 and cartilage degeneration in OA.

5.3
5.3.1

Limitations of Research
Limitations of in vivo models

As with any study there are limiting factors that may have influenced the conclusions that
I have come to. The single largest limiting factor in this thesis is perhaps also one of its
greatest strengths, the holistic in vivo nature of my mouse models. These models have
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allowed me to evaluate the role of Mig-6 and DUSP-1 in the context of the whole joint,
with all the systemic, biomechanical, and environmental factors intact. However, we are
inherently unable to completely control for all variables involved including: animal
behaviour (fighting, activity, etc.), genetic drift [59], housing conditions, litter size, and
likely many additional unknown factors. These effects may have been amplified by the
long term nature of some of my experiments. However, I attempted to account for some of
these issues by utilizing littermate control animals housed together with their respective
KO siblings wherever possible.
The relatively low N value for some experiments conducted may have impacted the validity
of some conclusions. The 21 month aging studies for constitutive cartilage-specific Mig-6
KO may have been particularly susceptible with an N of only 3 for many evaluations made.
To increase the N for some experiments particularly vulnerable to variability and noise
within the data, I utilized an additional pair of age matched controls, and noted this in the
appropriate locations of the chapter. However, despite the low N value, I was able to show
significant differences between KO and control animals in a number of variables assessed,
which further emphasizes the magnitude of these differences. Additionally, Mig-6 KO Tgfa
null experiments utilized an N of 2 female, and 1 male trials. While I have observed similar
phenotypic development in both male and female animals, it is possible that the mixed sex
of the animals used in this experiment influenced the findings. Experiments are under way
to increase the N for all of these studies, but due to the long duration of the studies and the
complex breeding for double KO mice, results won’t be available for several months.
Catwalk generated gait data proved particularly difficult to obtain ‘clean’ results. Previous
studies using this system utilized a number of animals nearly double the size of many of
my experiments, and still suffered from large variability within the data [60]. Therefore,
future studies may need to drastically increase the number of animals used, if reliable gait
data is to be evaluated using this system. However, in general we have not seen strong
effects in this version of the CatWalk system (Noldus CatWalk 7.1) using multiple models
of OA (Beier lab, unpublished).
I heavily utilized chemical staining and immunostaining techniques throughout the studies
presented in this thesis. While these techniques are extremely useful for the visualization
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of tissue damage, morphology and so on, they are difficult to quantify accurately. I made
every attempt to ensure that the histological techniques used accurately present the
pathology described, however additional molecular techniques (qPCR, Western Blotting,
etc.) may have revealed additional tissue effects missed by my methodology. In upcoming
follow-up work, I intend to employ these molecular techniques whenever possible.
The tamoxifen inducible Col2a1-CreER [20] system I utilized to selectively delete Mig-6
[10] from chondrocytes is inherently limited by its ability to express the CreER fusion
protein only while Col2a1 is being actively transcribed by the chondrocytes. This means
that recombination efficiency may have been affected at the age we chose to deliver
tamoxifen (21 days of age, weaning), despite evidence indicating adequate recombination
in articular chondrocytes in mice 1 month of age using a similar injection protocol [20].
This age was chosen for a variety of practical reasons, as mothers tend to reject young mice
injected prior to weaning (personal observation), and animals at this age tend to tolerate
intraperitoneal tamoxifen injections well. I am currently in the process of repeating these
experiments using a tamoxifen inducible Agc1-CreER(T2) mouse line [61] that drives
efficient CreER expression and subsequent recombination in articular chondrocytes
transcribing the aggrecan gene, even in 6 month old animals.
The constitutive cartilage-specific Mig-6 KO mice were established by using the Col2a1Cre [15] and Mig-6fl/fl [10] described in detail above. The nature of this type of tissuespecific KO necessitates that recombination occurs during embryonic growth, resulting in
deletion of Mig-6 during development as well as in adult tissue. While it is possible that
this influenced the development of the bones and joints of KO mice, I did not observe
significant differences in the long bone lengths of mice at 40 days of age, and previous
studies have not described skeletal growth phenotypes [9,10,28,29,32]. The Col2a1-CreER
experiments were conducted in part to address these possible effects.
Recent work utilizing classical and inducible Cre inserted directly into the
endogenous collagen X gene (Col10a1) in combination with various reporter systems has
demonstrated that during the process of endochondral ossification, a subset of hypertrophic
chondrocytes contribute to the osteoblast pool, perhaps through a trans-differentiation
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mechanism [62–65]. This may have serious implications for the ‘cartilage specificity’ of
our Col2a1-Cre driver line as at least some of the osteoblasts, and descendent osteocytes,
contributing to trabecular bone will exhibit recombination and could thus be deficient in
Mig-6 [66]. These findings may affect the interpretation of osteoclast activity shown by
increased TRAP staining in the trabeculae of Mig-6 KO mice in Chapter 2, which may
have been influenced by loss of Mig-6 in the resident osteoblasts and osteocytes. However,
based on these studies my data does support findings that show that increased EGFR
signalling in osteoblasts increases the recruitment of osteoclasts [6,19]. Similarly, a recent
study has also shown that a Col2a1-Cre driver similar to the one used in my studies induces
recombination in the knee joint synovium [41]. As I have observed ectopic growths in joint
regions associated with the synovium in Mig-6 KO mice, it is possible that these noncartilaginous tissues contribute to the formation of ectopic nodules in the knee joint.
Further research is still needed to establish the exact tissue(s) of origin for ectopic nodules
using my mouse models, although my lineage tracing experiments (Chapter 3) suggest that
the nodules are derived from cells expressing Cre in a cell-autonomous manner. Similar to
studies described above, we are in the process of increasing the N for these experiments to
obtain conclusive evidence for this.
Unfortunately, I was unable to directly demonstrate that Mig-6 protein is not present
specifically in targeted KO tissues, as efforts to utilize a Mig-6 antibody for
immunostaining have largely failed in my hands. PCR evidence of recombination was
certainly contaminated by tissues not expressing Col2a1 and is simply a confirmation that
at least some recombination is occurring. Supplementary data provided using a
ROSA26mTmG dual reporter system provides some evidence that CreER mediated deletion
is taking place in the chondrocytes of CreER(+) mice injected with tamoxifen, but is
severely limited by an N value of 1.
While my studies and others demonstrate evidence for the role of EGFR signalling
mediating the results observed in Mig-6 KO mice [28,29,32], I cannot be sure that this is
due exclusively to Mig-6—EGFR interactions. Mig-6 binds to a number of candidate
proteins that may have contributed to the phenotypes described including: all 4 of the
EGFR family receptors (ErbB1-4), MET, c-Abl and Cdc42 [67,68]. However, little is
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known about the overall effects of Mig-6 interactions with these alternative binding
partners, particularly their roles in cartilage in vivo [67,68], and so additional work is
required to elucidate their function in the phenotypes I have described.
The whole body Dusp1 KO mice utilized in my studies were generated through the
insertion of the commonly used neomycin cassette into the Dusp1 gene, disrupting exon 2
and reducing DUSP-1 protein expression to undetectable levels [26]. Since the deletion of
Dusp1 affects all tissues in the body of these animals, it is possible that loss of DUSP-1
protein in various tissues may have influenced hormonal signalling, muscle function
(important in joint alignment and gait analysis), metabolism, behaviour, or the immune
system in unexpected ways that may have affected disease progression in KO mice. In
addition, since Dusp1 is also constitutively removed during embryonic stages, the
development of Dusp1 KO mice may have been altered in such a way that the clinical
relevance may be influenced as discussed above.
Furthermore, a report that Dusp1 KO mice develop spontaneous osteolytic disease in the
toes at approximately 20-24 months of age [24] may indicate that pathology unrelated to
OA may have been captured in our experiments. Gait analysis in particular would be
susceptible to misinterpretation of results. However, we did not observe any obvious
evidence of toe swelling in a colony of greater than 20 KO animals over the course of this
study. Overall, the fact that aging-associated osteoarthritis did not appear to be altered in
the Dusp1 KO mice suggests that global deletion of the gene did not induce systemic effects
influencing our findings.

5.4

Future Directions

A number of future studies could be established to expand on, and further elucidate the
findings of this thesis. While I have shown a number of Mig-6 KO related phenotypes in
vivo, these results need to be scrutinized in an in vitro environment where additional
variables can be adequately controlled for. In particular, we still lack sufficient data to
conclusively describe a mechanism for both anabolic growth of chondro-osseous nodules,
and increased articular cartilage thickness observed in my Mig-6 KO mice. With this in
mind, there are a number of different proteins that interact directly or indirectly with Mig-
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6 (ex. MET, c-Abl, Cdc42) and may be partially responsible for the phenotypes I have
described. Interaction between these factors and Mig-6 could be examined using in vitro
cell and tissue culture methods with cells isolated from Mig-6fl/fl to further elucidate a
mechanism for chondrocyte proliferation and activation of cartilage neogenesis and
ossification. These studies will also help to reveal which of the phenotypes in our mutant
animals are due to altered EGFR signalling, and which are due to other pathways. Similarly
the viability of Mig-6 and EGFR signalling pathways for use in expanding chondrocytes,
or ex vivo cartilage tissue itself for use in cartilage regenerative techniques could also be
examined.
Early attempts to utilize Mig-6 KO mice for use in experiments based on surgical induction
of OA [16] failed due to the formation of ectopic tissue physically blocking surgical access
to the joint. While I did not observe any notable phenotypes in heterozygous Mig6fl/+
Col2a1-Cre+/- mice during my studies (data not shown), these animals may respond in an
interesting fashion to models of post-traumatic OA. Based on the findings of this thesis,
these animals may show protection from cartilage degeneration in these models, and
perhaps with greater incidence of bony osteophyte formation. Regardless, these studies
would help to evaluate the potential of Mig-6 and EGFR signalling as therapeutic targets
in post-traumatic OA. In addition, conditional KO in the cartilage just prior or after surgery
would be interesting. Given the limitations of the Col2-CreER driver described above, we
have bred our conditional Mig-6 KO mice with the Agc1-CreER(T2) mice [61] that confer
more robust recombination in postnatal articular cartilage. This strategy will permit the use
of the DMM surgical model as well as allow for more detailed functional studies on the
development of the ectopic nodules.
Tissue from human diseases exhibiting similar pathological features (ex. enchondromas,
osteochondromas [69]) as the ectopic nodules in my Mig-6 KO mice, would be valuable to
examine for Mig-6 mediated effects. However, the rarity of these diseases and difficulty
obtaining samples may make this line of study difficult.
Furthermore, while I have performed a number of Mig-6 loss of function studies described
in this thesis, gain of function studies could further elucidate the function of Mig-6 and

209

EGFR signalling in cartilage. In fact, a conditional Mig-6 overexpressing line of mice has
recently been developed that would be well suited for both in vivo and in vitro study designs
[70].
While I have evaluated the role of DUSP-1 in spontaneous OA and found its influence to
be largely lacking, the role of this protein in post-traumatic OA has not been assessed.
These studies may prove particularly interesting as DUSP-1 appears to be closely involved
with inflammation [23–25] that appears to play a key role in the formation of posttraumatic OA [71]. Furthermore, additional DUSP proteins could be examined for their
role in cartilage homeostasis in vitro and in vivo [21]. DUSP-5 in particular appears to act
similarly to DUSP-1 in an inflammatory model of arthritis, and may be an interesting target
for future studies [72].
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